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Abstract 
 This Ph.D. thesis focuses on the engineering of an efficient and 
enantioselective biocatalyst via direct evolution and genetic engineering for the 
enantioselective hydroxylation of non-activated carbon atom, a useful but challenging 
reaction for the synthesis of chiral pharmaceutical intermediates. Our target enzyme is 
the novel P450pyr enzyme from Sphingomonas sp. HXN-200 that was found to 
catalyze the regio- and stereoselective hydroxylation of non-activated carbon atom 
with broad substrate range, high activity, excellent regioselectivity, and good to 
excellent enantioselectivity. Our target reaction is the enzymatic hydroxylation of N-
benzyl pyrrolidine to its corresponding (R)- and (S)-N-benzyl-3-hydroxypyrrolidines 
which are important pharmaceutical intermediates. 
 In this thesis, a two-enzyme-based colorimetric high-throughput ee screening 
assay and a mass spectrometry-based high-throughput ee screening assay were 
developed. The P450pyr monooxygenase was engineered by directed evolution for 
the enantioselective hydroxylation of N-benzyl pyrrolidine. Several mutants 
exhibiting increased and/or inverted enantioselectivity were identified, with 
product ee of 83% (R) and 65% (S) for mutants 1AF4A and 11BB12, respectively. 
The wild type P450pyr and its mutants were also purified and reconstituted with their 
auxiliary electron transport proteins, ferredoxin and ferredoxin reductase in vitro. The 
mutants were then used to catalyze the hydroxylations of a range of different 
substrates using whole-cell assays to investigate the changes in product ee. In addition, 
an efficient biocatalytic system with cofactor recycling was developed by co-
expressing a glucose dehydrogenase from Bacillus substilis or a phosphite 
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dehydrogenase from Pseudomonas stutzeri together with the P450pyr system in a 
recombinant Escherichia coli. 
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Chapter 1 : Introduction 
1.1 Industrial Biotechnology 
 Industrial biotechnology, also known as white biotechnology, is the 
application of modern biotechnology to the sustainable production of chemicals 
(which includes fine chemicals and pharmaceuticals), materials, and fuels from 
renewable sources, using living cells and/or their enzymes.  This field is widely 
regarded as the third wave of biotechnology, distinct from the first two waves 
(medical or red biotechnology and agricultural or green biotechnology).  Much 
interest has been generated in this field mainly because industrial biotechnology is 
often associated with reduced energy consumption, greenhouse gas emissions, and 
waste generation, and also may enable the paradigm shift from fossil fuel-based to 
bio-based production of value-added chemicals. 
 The fundamental force that drives the development and implementation of 
industrial biotechnology is the market economy, as biotechnology promises highly 
efficient processes at lower operating and capital expenditures. In addition, political 
and societal demands for sustainability and environment-friendly industrial 
production systems, coupled with the depletion of crude oil reserves and a growing 
world demand for raw materials and energy, will continue to drive this trend forward.1  
McKinsey & Company predicted that in 2010 industrial biotechnology will account 
for 10 percent of sales within the chemical industry, amounting to US$125 billion in 
value (http://www.chemie.de/news/e/pdf/news_chemie.de_56388.pdf).  In the US, 
bio-based pharmaceuticals account for the largest share of the biotechnology market 
followed by bio-ethanol, other bio-based chemicals, and bio-diesel.2  Other major 
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players in industrial biotechnology include the European Union,3,4 China, India, and 
Brazil.  In China alone, the value of bio-based chemical products exceeded US$60.5 
billion in 2007.5 
 Government policies including tax incentives, mandatory-use regulations, 
research and development, commercialization support, loan guarantees, and 
agricultural feedstock support programs have helped fuel the adoption of industrial 
biotechnology.  Moreover, breakthroughs in enzyme engineering, metabolic 
engineering, synthetic biology, and the expanding ‘omics’ toolbox coupled with 
computational systems biology are expected to speed up industrial application of 
biotechnology. These advances have provided scientists with toolsets to engineer 
enzymes and whole-cells, by expanding the means to identify, understand and make 
perturbations to the complex machinery within the microorganisms. 
1.2 Chemo-, Regio- and Enantioselective Biocatalysis 
 Biocatalysis is one of the oldest chemical transformations known to humans, 
with the oldest records of brewing dating back to about 6000 years ago. The 
employment of enzymes and whole-cells in chemical, pharmaceutical, as well as food, 
textile and paper industries is increasing rapidly. Whole-cells are often used in 
reactions which require the regeneration of expensive cofactors, whereas isolated 
enzymes are typically used for hydrolytic or isomerization reactions. Nevertheless, in 
industrial settings, whole-cells are usually preferred over purified enzymes, even for 
single step transformations, to avoid enzyme purification costs.  
 Biocatalysis offers several significant advantages over chemocatalysts. Firstly, 
since enzymes function at moderate temperatures and pressures, they require less 
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energy input. Secondly, enzymes can be extremely fast, increasing reaction rates by 4 
to 12 orders of magnitude. In some cases, enzymes can be so fast that their turnover 
rates are limited only by diffusion of substrate(s) and product(s) to and from the active 
site. Thirdly, since biocatalysts are biodegradable and rarely contain heavy metals, 
waste streams are much more manageable, requiring minimal treatment. Fourthly, 
since most biocatalysts function in aqueous media, effluent volatile organic 
compound (VOC) emissions from production plants can be drastically reduced. Lastly 
but most importantly, enzymes can be highly selective (regio-, diastereo-, enantio-, or 
chemo-), and thus are able to replace multistep reactions or difficult purification 
schemes. This can circumvent the need for many blocking and deblocking steps that 
are required for stereo- or regio-selective reactions.  
 The high selectivities of enzyme make them attractive for industrial 
applications due to its increased product concentrations and productivities besides 
having no undesirable by-products. Despite the considerable progress in chiral 
synthesis, organic chemists are still struggling with the complexity of using traditional 
organic chemistry to synthesize chiral compounds. Thus, the focus is now switched to 
biocatalysis - a simple yet efficient method to synthesize enantiopure compounds as 
chiral building blocks for drugs and agrochemicals. The use of biocatalysis to produce 
enantiopure compounds can be divided into two approaches: (1) kinetic resolution of 
a racemic mixture where the enzyme is used to convert one of the enantiomers at a 
higher reaction rate than the other enantiomer; and (2) asymmetric biocatalysis 
starting with a prochiral substrate to produce different enantiomers in different 
quantities. 
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 Chirality is a very important factor in the efficacy of many drug products. A 
survey of major pharmaceutical companies such as GlaxoSmithKline (UK), 
AstraZeneca (UK) and Pfizer (US) showed that more than half of the drug compounds 
examined contained one or more chiral centers.6 Furthermore, an enantiomeric purity 
of at least 99.5% is often necessary to meet regulatory requirements.  Selectivities 
of >95% are difficult to achieve by chemocatalysis and, if essential to synthesis, 
would require the use of biocatalysis. At present, 22 of 38 large-scale asymmetric 
syntheses already incorporated biocatalysis.7 Recognizing its importance, many fine 
chemical and pharmaceutical companies have started to focus on acquiring 
biocatalysis expertise (Table 1.1), and those that have already done so are trying to 
maintain their positions as technological leaders. 
Table 1.1. Biotransformations developed by the pharmaceutical industry.8 
Target compound Company Reaction Biocatalyst 
SCH56592 Schering Plough Acylation CALB 
β-Lactams Glaxo Smith Kline Acylation CALB 
Lotrafiban Glaxo Smith Kline Hydrolysis CALB 
Paclitaxel Bristol-Myers 
Squibb 
Hydrolysis Pseudomonas 
lipase AK 
P. cepacia lipase 
PS-30 
HMG-CoA 
reductase inhibitor 
Bristol-Myers 
Squibb 
Acylation P. cepacia lipase 
PS-30 
SCH66336 Schering Plough Acylation P. aeruginosa 
lipase 
Xemilofiban Monsanto Hydrolysis E. coli penicillin 
acylase 
Renin inhibitor Hoffmann La 
Roche 
Hydrolysis B. licheniformis 
subtilisin 
Lamivudine Glaxo Smith Kline Hydrolysis E. coli cytidine 
deaminase 
AG7088 Pfizer Reduction L. mesenteroides D-
LDH 
C. boidinii FDH 
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ACE inhibitor Ciba-Geigy Reduction S. epidermis D-
LDH 
LY300164 Eli Lilly Reduction Z. rouxii 
dehydrogenase 
Omapatrilat Bristol-Myers 
Squibb 
Reductive 
amination 
T. intermedius PDH 
N-Butyl DNJ Pharmacia Oxidation G. oxydans SDH 
2-Quinoxaline-
carboxylic acid 
Pfizer Oxidation A. repens MO 
HMG-CoA 
reductase inhibitor 
Merck Sharp and 
Dohme 
Oxidation N. autotropica MO 
Lobucavir prodrug Bristol-Myers 
Squibb 
Regioselective 
acylation 
B. licheniformis 
subtilisin 
CALB: Candida antartica lipase, FDH: formate dehydorgenase, D-LDH: D-lactate dehydrogenase, MO: 
monooxygenase, PDH: phenylalanine dehydrogenase, SDH: sorbitol dehydrogenase. 
 
1.3 Enzymatic Hydroxylation of Non-Activated Hydrocarbons 
 Regio- and stereoselective hydroxylations of non-activated carbon atoms 
represent a significant challenge in classical organic chemistry.9 However, this 
reaction can be carried out via biocatalysis with monooxygenases using molecular 
oxygen as oxidant. Several monooxygenases such as cytochrome P450cam, P450BM-
3, methane monooxygenases (MMO) and membrane-bound alkane hydroxylase (alkB) 
have been extensively investigated. These biohydroxylations are very useful for the 
preparation of enantiopure compounds that are useful pharmaceutical intermediates. 
1.3.1 Cytochrome P450 Monooxygenase 
 First discovered about 50 years ago, cytochrome P450 enzymes constitute the 
largest superfamily of heme-containing monooxygenases (E.C.1.14.-.-) that have the 
ability to oxidize a broad range of substrates, often at non-reactive carbon centers.10 
The name cytochrome P450 is derived from the following: cytochrome stands for a 
hemoprotein, P for pigment, and 450 reflects the absorption peak of the reduced CO-
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bound complex at 450 nm. Cytochrome P450s are widely distributed in prokaryotes 
and eukaryotes, with over 11,000 P450s identified to date 
(http://drnelson.uthsc.edu/CytochromeP450.htmL). The sequence of the P450 
polypeptide chain can be quite diverse with P450s from the same family differing by 
up to 60% in their amino acid sequence. 
 P450 enzymes can be divided into four classes, depending on their redox 
partners. Class I P450s include most bacterial monooxygenases that require a FAD-
containing reductase and an iron sulfur redoxin (P450cam from Pseudomonas putida). 
Class II enzymes require only a FAD/FMN-containing P450 reductase for the transfer 
of electrons and are found mostly attached to the endoplasmatic reticulum. P450BM-3 
from Bacillus megaterium, CYP102A2 from Bacillus subtilis and CYP505from 
Fusarium oxysporum belong to this class of enzymes. They are self-sufficient as they 
contain the P450 monooxygenase and the reductase domain on a single peptide chain. 
Class III enzymes are self-sufficient and require no electron donor as they convert 
peroxygenated substrates that already contain oxygen. Meanwhile, P450s from class 
IV receive electrons directly from NAD(P)H (P450nor from F. oxysporum). 
 The most common hydroxylation reaction catalyzed by cytochrome P450 is 
the insertion of one atom of oxygen into a nonactivated carbon atom of an organic 
substrate (RH), which is not possible by standard chemical methods, while the other 
oxygen atom is reduced to water.  
R-H + O2 + 2e- + 2H+
P450
R-OH + H2O
NAD(P)H NAD(P)+  
Scheme 1.1. General hydroxylation reaction catalyzed by P450 monooxygenases. 
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 The catalytic turnover of cytochrome P450 begins with the binding of 
substrate followed by the introduction of the first electron from NADPH via an 
electron transfer chain.11 Next, the oxygen binds and accepts a second electron to 
produce a ferric peroxy anion. This anion is protonated to form the ferric hydroperoxy 
complex, which is subjected to a heterolytic cleavage with the formation of a putative 
ferryl species, equivalent to a Fe(V)=O species. This reactive electrophilic iron-oxo 
intermediate then attacks the substrate to yield the hydroxylated product, which 
dissociates to allow the cycle to begin again. 
 Cytochrome P450s are involved in the biotransformation of drugs, the 
bioconversion of xenobiotics, the metabolism of chemical carcinogens, the 
biosynthesis of physiologically important compounds such as steroids, fatty acids, 
eicosanoids, fat-soluble vitamins, bile acids, the conversion of alkanes, terpenes and 
aromatic compounds as well as the degradation of herbicides and insecticides.11 P450s 
are involved in diverse reactions including hydroxylation, N-, O-, S-dealkylation, 
sulphoxidation, epoxidation, deamination, desulphuration, dehalogenation, 
peroxidation and N-oxide reduction.12 P450s can also catalyze multi-step reactions. 
One example is the transformation of artemisinic acid, a precursor of the antimalarial 
drug artemisin, by CYP71AV1.13 In this example, amorpha-4,11-diene, a natural 
product of E. coli or Saccharomyces cerevisiae, was initially hydroxylated twice by 
CYP71AV1. The hydroxylation product was spontaneously dehydrated to form an 
aldehyde which was subsequently converted by CYP71AV1 to form artemisinic acid. 
In another example, P450scc was used to convert cholesterol by two successive 
hydroxylation reactions into (20R, 22R),20,22-dihydroxycholesterol. The P450scc was 
then used to catalyze the C-C bond cleavage to yield prenenolone and isocaproic 
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acid.14 Despite the large application scope of P450 enzymes as biocatalysts, they are 
rarely implemented in industrial processes mainly due to their instability, complexity 
and often low catalytic turnover.15 Nevertheless, with the increasing advancement in 
the powerful methodologies of genetic engineering, P450 enzymes can now be 
engineered with tailor-made properties, such as the engineering of recombinant 
expression, physical properties, catalytic activity and interactions with redox 
partners.16 
1.3.2 Methane Monooxygenases 
 Methane monooxygenase (MMO) belongs to the class of oxidoreductase 
enzymes (EC 1.14.13.25) and is able to oxidize the C-H bond in methane as well as 
other alkanes. There are two well-investigated forms of MMO: the soluble form 
(sMMO) and the particulate form (pMMO). The active site in sMMO contains a di-
iron center bridged by an oxygen atom (Fe-O-Fe), whereas the active site in pMMO 
utilizes copper. Over the decades, intensive investigation of these hydroxylation 
reactions have been carried out either with the methanogenic microorganisms or 
purified enzymes.17,18 Methane monooxygenases (MMOs) isolated from 
Methylococcus capsulatus Bath and Methylosinus trichosporium OB3b are found to 
be able to hydroxylate simple alkanes with NADH as cofactor.19 The MMO from 
Methylococcus capsulatus is able to hydroxylate a series of simple alkanes to alcohols, 
such as n-pentane to (R)-2-pentanol, although the yields are significantly reduced with 
increasing chain lengths in the substrates.17 
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1.3.3 Membrane-bound Alkane Hydroxylase (AlkB) 
 AlkB is an integral membrane non-heme iron protein that was first discovered 
in a hexane-degrading pseudomonad known as Pseudomonas putida GPo1.20 The 
AlkB system consists of three components: the AlkB monooxygenase, rubredoxin and 
the electron-providing NADH-dependent flavoprotein rubredoxin reductase. The 
AlkB enzymes are very diverse and have different substrate ranges with the capability 
to oxidize C5 to C16 n-alkanes, as well as branched, cyclic aliphatic and aromatic 
compounds.21 Extensive work has been carried out to understand the structure-
function relationship of this class of enzyme. One interesting example is a protein 
engineering study where a tryptophan residue located in the middle of one of six 
transmembrane helices was found to limit the length of the alkane substrates.22 
1.4 Protein Engineering 
 One of the most important tools for industrial biotechnology is protein 
engineering.  More often than not, a wild-type enzyme discovered in nature is not 
suitable for an industrial process.  There is a need to engineer and optimize enzyme 
performance in terms of activity, selectivity on non-natural substrates, thermostability, 
tolerance towards organic solvents, enantioselectivity, and substrate/product 
inhibition among others in order for the enzymatic process to be commercially 
viable23 (Figure 1.1). There are two general approaches for protein engineering: 
rational design and directed evolution. 
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2C5, Kumar and colleagues have also rationally engineered the P450 2B1 to alter the 
regioselectivity of progesterone metabolism from 16α- to 21-hydroxylation.29 
1.4.2 Directed Evolution 
 Directed evolution is a powerful tool for tailoring enzyme functions in order to 
close the functional gap between the naturally occurring protein and one that is 
commercially viable.30-33 Inspired by natural Darwinian evolution, directed evolution 
involves creation of genetic diversity via methods such as error-prone polymerase 
chain reaction (epPCR), saturation mutagenesis, DNA shuffling34 and Staggered 
Extension Process (StEP)35, followed by screening and/or selection for mutants with 
desired features. Compared to the natural evolution of species which may take 
millions of years, directed evolution can be carried out within months and with a 
greater number of parents. Hence, directed evolution is a fast way to develop 
biocatalysts which have desired characteristics. The advantage of directed evolution 
over rational design is that it does not need any structural or mechanistic information 
of the protein of interest and can be carried out with just the knowledge of the gene 
sequence.   
 For example, error-prone PCR and site saturation mutagenesis have been used 
to engineer the activity and regioselectivity of the cytochrome P450 BM-336.  Iterative 
site-specific saturation mutagenesis has also been used to alter the ligand-binding 
specificity of the human estrogen receptor α (hERα) to recognize non-steroidal 
synthetic compounds37-39 and xylose-specific xylose reductase for xylitol synthesis.40  
In addition, a family shuffling approach was used to increase the catalytic activity and 
thermostability of a type III polyketide synthase, PhlD from the soil bacterium 
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Pseudomonas fluorescens Pf-5.41  A summary of directed evolution techniques is 
shown in Table 1.2. 
Table 1.2. Summary of the advantages and disadvantages of selected directed evolution methods 
(Adapted from Rubin-Pitel and coworkers42). 
Technique Advantages Disadvantages 
epPCR Simplicity 
Tunable mutation rate 
Biased mutagenesis 
SeSaM Unbiased mutagenesis 
Codon randomization possible 
2-3 days to perform 
Several steps, reagents & 
enzymes required 
Special primers required 
Several purification steps 
involved 
RID Random insertions and deletion 
Large diversity possible 
Codon randomization possible 
Several steps, reagents & 
enzymes required 
Frameshift mutations possible 
RAISE Random insertions and deletion 
Codon randomization possible 
Frameshift mutations possible 
DNaseI digestion bias 
DNA 
Shuffling 
Robust, flexible 
Back-crossing to parent removes non-
essential mutations 
Synergistic/additive mutations can be 
found 
DNaseI digestion bias 
Biased to crossovers in high 
homology regions 
Low crossover rate 
High percentage of parent 
Family 
Shuffling 
Exploits natural diversity 
Accelerated phenotype improvement 
DNaseI digestion bias 
Biased to crossover in high 
homology regions 
Need high sequence 
homology in family 
Low crossover rate 
High percentage of parent 
RACHITT No parent genes in shuffled library 
Higher rate of recombination 
Recombine genes of low sequence 
homology 
Several steps, reagents & 
enzymes required 
Requires synthesis and 
fragmentation of single-
stranded complement DNA 
NExT DNA 
Shuffling 
Predictable fragmentation pattern 
 
Non-random fragmentation 
Several steps, reagents & 
enzymes required 
Toxic piperidine used 
StEP Simplicity Need high homology 
Low crossover rate 
Need tight control of PCR
CLERY Not limited by ligation efficiency of 
gene into vector 
Transformants contain more 
than one mutant, so rescue 
and retransformation required 
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Long PCR program for 
reassembly 
DNaseI digestion bias 
Background mutation in 
plasmid possible 
Limited diversity 
ITCHY Eliminates recombination bias 
Structural knowledge not needed 
Completely homology-independent 
Limited to two parents 
One crossover per iteration 
Significant fraction of 
progeny out-of-frame 
Complex, labor-intensive 
Single crossovers 
SCRATCHY Eliminates recombination bias 
Structural knowledge not needed 
Multiple crossovers possible 
Limited to two parents 
Significant fraction of 
progeny out-of-frame 
Complex, labor-intensive 
DNaseI digestion bias 
 
1.4.2.1 Directed Evolution of P450 Monooxygenases 
 By combining error-prone PCR (epPCR) and in vitro recombination, Glieder 
et al. have evolved a converted the P450 BM-3 from a fatty acid monooxygenase into 
one that can hydroxylate hexane and other alkanes with high activity.43 In fact, the 
hydroxylation turnover rates of all the liquid alkanes exceed those of the wild type 
P450 BM-3. The improved mutant enzyme contains 11 amino acid substitutions with 
only one mutation that is in direct contact with the substrate. The work did not stop 
there as the P450 BM-3 was further evolved by many rounds of DNA shuffling and 
recombination, site saturation mutagenesis, site directed mutagenesis, and random 
mutagenesis in order to finally obtain a P450 propane monooxygenase (P450 PMO).44 
This newly evolved enzyme was shown to have a ~9000-fold increase in kcat/KM. This 
demonstrates that directed evolution can be used to completely respecialize the 
cytochrome P450 for function on a nonnative substrate. In another directed evolution 
experiment, the regioselectivity of CYP102A3 from Bacillus substilis was evolved to 
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hydroxylate substrates at different subterminals, and especially at terminal carbon 
chain positions.45 
 One main problem in utilizing enzymes at industrial level is its poor tolerance 
towards organic cosolvents, which is often necessary especially when using high 
substrate concentrations.  To address this issue, Wong et al. used epPCR and 
saturation mutagenesis to introduce mutations that significantly improve the activity 
of P450 BM03 and its F87A mutant in the presence of acetone, acetonitrile, 
dimethylformamide (DMF), dimethylsulfoxide (DMSO), ethanol, and tetrahydrofuran 
(THF).46 In this work, mutants containing a small alanine residue at position 87 have 
been found to have lower organic solvent tolerance compared to variants with 
phenylalanine at the same position, as the bulky phenylalanine lies perpendicular to 
the catalytic heme center and is likely to restrict the access of organic cosolvent to the 
heme.  
  Many industrial applications require enzymes that retain their function at 
elevated temperatures.  Arnold and colleagues has reported the evolution of a 
thermostable P450 BM-3 peroxygenase 21B3 resulting in a mutant which is more 
thermostable than the wild type P450 BM-3, but retains most of the peroxygenase 
activity of 21B3.47 
1.4.3 Screening and Selection 
 Often, finding an enzyme with desirable properties in a library of mutants 
generated by directed evolution is akin to looking for a needle in a haystack.  Over the 
past several years, a multitude of screening and/or selection techniques have been 
developed to isolate the variants of interest.  An example of a selection method was 
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described by Boersma and coworkers in the directed evolution of B. subtilis lipase A 
variants with inverted and improved enantioselectivity.48  The method is based on the 
use of an Escherichia coli aspartate auxotroph, the growth of which is dependent upon 
hydrolysis of an enantiomerically pure aspartate ester by desired lipase variants.  A 
covalently binding phosphonate ester of the opposite enantiomer was used as a suicide 
inhibitor to inactivate less enantioselective variants. 
 
Figure 1.2. A typical screening procedure in a 96-well microtiter plate format 
 Another commonly used method is microtiter plate-based screening.  A typical 
screening procedure in a 96-well microtiter plate format begins with the generation of 
a library of mutants which are picked and grown in 96-well plates.  The proteins of 
interest are expressed and are often subjected to a high-throughput assay based on 
UV-absorption, fluorescence or colorimetric methods.  Mutants displaying desired 
characteristics are then verified and sequenced.  The best mutant is then selected as 
the template for the next round of mutagenesis.  The process is repeated in an iterative 
manner until the goal is achieved or no further improvements are possible (Figure 1.2).  
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Other screening/selection methods include the agar plate screen, cell-in-droplet screen, 
cell as microreactor, cell surface display, and in vitro compartmentalization, which 
has been described in earlier reviews.49,50 Despite the availability of a wide range of 
screening or selection tools, their applicability is often specific only to a particular 
substrate/enzyme combination and much effort is still required to customize and 
optimize a screening/selection method for different directed evolution approaches. 
1.4.3.1 High-Throughput Screening Methods for Assaying Enantioselective 
Enzymes and Biocatalysts 
 High-throughput screening methods for assaying the enantioselectivity of 
enzymes can be divided into three categories: (1) assays used for biotransformation 
from a racemic substrate, (2) assays used for asymmetric catalysis from prochiral 
substrate, and (3) assays used to quantify the enantiomeric products from an 
enzymatic reaction.  
Assays for enantioselective biotransformation from racemic substrate 
 Enantioselective enzymatic biotransformation in which an enzyme selectively 
converts one of the enantiomers of a racemic substrate to product, or also known as 
kinetic resolution, is the most common basis used in the development of a high-
throughput assay. In assays where the ratio of reaction rates of enantiomeric 
substrates is used to predict the enantiomeric ratio E of a catalyst, the condition is the 
assay concentration lies below the Michaelis-Menten constant KM for each 
enantiomer i.e. very dilute substrate concentration. 
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 One of the earliest high-throughput UV/Vis-based method was an assay 
developed for the lipase-catalyzed kinetic resolution of chiral p-nitrophenol esters, 
with the goal of evolving highly enantioselective mutants of the lipase from 
Pseudomonas aeruginosa.51 Lipase-catalyzed hydrolysis generates p-nitrophenolate 
which shows a strong UV/Vis absorption at 405nm. The (R)- and the (S)-esters were 
tested separately pairwise on a 96-well microtiter plate using a simple UV/Vis-based 
plate reader, enabling 48 mutants to be screened in a few minutes.  This system has a 
few drawbacks such as the need for pure enantiomers, requirement of a built-in 
chromophore (p-nitrophenol), whose presence in the substrate may misdirect the 
results in a directed evolution experiment, and also the need for clear solutions for 
spectrophotometric measurements. Also, since the (S)- and (R)-substrates are tested 
separately pairwise, the competitive binding of enantiomers to the enzyme has been 
ignored. This may lead to erroneous results in the estimated enantiomeric ratio, E 
(errors up to ±70%) as the contribution of KM to the overall selectivity of the enzyme 
has been ignored. 
 To minimize this error, the Quick E method made use of a reference 
compound resorufin tetradecanoate to introduce some competitive binding in the 
enzymatic reaction.52 This method allows the (S)- and (R)-substrates to compete 
against each other indirectly by competing each enantiomer against a reference 
compound. The pH indicator assay, on the other hand,53 utilizes the indicator color 
change which correlates to the number of proton released during the hydrolysis of 
esters such that the need for a built-in chromophore is obviated. 
 Assays based on fluorescence to screen for enantioselectivity is attractive due 
to its high sensitivity (allows for use of very diluted substrates or small amounts of 
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catalysts), simplicity and possibility of real-time analysis. This has been demonstrated 
by Tumambac and Wolf using a C2-symmetric fluorosensor (1,8-
diquinolylnaphthalene N,N’-dioxide) employed in real-time enantioselective analysis 
of the enzymatic kinetic resolution of racemic trans-1,2-diaminocyclohexane.54 
Adding the fluorosensor to (R,R)-3 significantly enhances fluorescence of the sensor, 
whereas the (S,S)-enantiomer has little effect. The fluorescence intensity was not 
affected by the addition or presence of other analytes such as bisamidoester and 
monoamidoester, implying that this screening method do not require tedious 
purification and derivatization steps. In the course of the reaction, as the fluorescence 
intensity decreased due to the decreasing relative amount of (R,R)-3, the enantiomeric 
excess, ee of the rac-3 can be monitored real-time. 
 Hwang and Kim demonstrated a Cu(II) amine complex formation method to 
measure the apparent enantioselectivity (Eapp) of ω-transaminase by measuring 
reaction rates of pure enantiomers (R)- and (S)-aromatic amines respectively.55 The 
product α-amino acids will form a blue complex with the Cu(II) ion, which is 
quantifiable using UV/Vis spectrophotometer. This method still requires some fine 
tuning as the Eapp value shows large errors when compared to the actual E value by 
HPLC analysis due to the neglect of the competitive binding of the two enantiomers 
to the enzyme. 
 The most direct method of screening would be to link improved enzyme 
activity to the survival or growth rates of cells which expresses the enzyme. Reetz and 
Rüggeberg demonstrated a differential growth method to screen for enantioselective 
enzymes without the need to harvest individual bacterial colonies.56 The ee-assay was 
based on the esterase-catalyzed enantioselective hydrolysis of a fluoroacetate of 
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pactolactone which leads to fluoroacetic acid – a toxic compound which inhibits the 
growth of esterase producing yeast. Cell density measurements (OD-values) of the 
yeast in culture medium were used to monitor the growth rate of the yeast. As yeast 
was found to be more selective towards the (S)-enantiomer, the culture medium 
containing the (S)-enantiomer showed an OD-value that was significantly lower than 
that of the (R)-enantiomer. The difference in the OD-values indicates the 
enantioselectivity of the yeast.  
 Significant advances have been made on the methods of chiral identification 
and quantification based on mass spectrometry. In studies involving kinetic resolution 
of racemates with 2D isotopic labeling, Reetz et al described an ee-assay based on 
ESI-MS which was used to quantify the ee of two lipase-catalyzed kinetic resolution 
examples: the hydrolysis of pseudo-racemic 1-phenylethyl acetate and the 
stereoselective esterification of a 1:1 pseudo-racemic mixture of 2-pheynylpropionic 
acid.57 In both cases, the (R)-enantiomer was labeled with the 2D isotope. About 1000 
ees determinations can be performed per day at an accuracy of ±5% (when compared 
to results from GC). The isotope-based MS assay has also been applied in the directed 
evolution of enantioselective epoxide hydrolase from Aspergillus niger, which were 
catalysts for the hydrolysis of racemic substrate (R)-styrene oxide and its deuterated 
pseudo enantiomer, (S)-D8-styrene oxide.58 The ratio of the pseudo-enantiomeric 
products can be measured by ESI-MS. 
 Another version of the isotope-labeling approach is NMR-based and 
dependent on the 13C-labeling of the (S)-enantiomer to create a pseudo racemic 
mixture of 1-phenylethyl acetate and 2-pheynylpropionic acid respectively.59 Upon 
catalytic hydrolysis, two pseudo enantiomers in the product mixture can be clearly 
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distinguished by 1H NMR spectroscopy and the ee value can be obtained by analyzing 
the NMR peaks. A throughput of 1400 ee determinations per day at an accuracy of 
±2-5% is possible with this method. 
 The general principle of isotope labeling is further applied to a Fourier 
transformed infrared spectroscopy (FTIR)-based assay.60 13C-labeling of the carbonyl 
groups was selected to allow easy reading and analysis of the vibrational bands in the 
IR spectrum. Pseudo-enantiomeric substrates used in this example were (R)-1-
phenylethyl acetate and (S)-(1-phenylethyl)-1-13C-acetate, as well as (R)-N-1-
phenylethylacetamide and (S)-N-(1-phenylethyl)-1-13C-acetamide. The shift of the 
respective carbonyl stretching vibration allowed the quantification of the pseudo-
enantiomers. Lambert-Beer’s law was applied in calculating the concentrations of 
these pseudo-enantiomers, thus requiring the determination of the molar coefficients 
of absorbance. This FTIR method is advantageous over the previously described 
NMR and MS approaches as the ee values in culture supernatants could be 
determined directly. Using an automated system, up to 10000 samples per day is 
possible by measuring the ee values in culture supernatants with an accuracy of ±7%. 
This method can be extended to the catalytic desymmetrization of prochiral 
compounds containing isotope labeling. 
Assays for enantioselective biotransformation from prochiral substrate 
 High-throughput assays have also been developed for screening 
enantioselective synthesis by which the catalyst forms a chiral product from an achiral 
substrate. 
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 Single stage mass spectrometry methods which include isotope labeling in 
studies involving desymmetrization of prochiral compounds bearing reactive 
enantiotopic groups have been introduced. A typical example is provided by a lipase-
catalyzed enantioselective hydrolysis of pseudo-meso-1,4-diacetoxy-2-cyclopentene 
(labeled with 2D) which afforded a mixture of pseudo-enantiomeric products that can 
be analyzed by MS.57 Although this method would involve the pre-preparation of 
pseudo-prochiral compounds, once this task is done, a large number of asymmetric 
reactions by a huge library of enzymes can be conducted in a high-throughput manner. 
In an industrial application, Diversa used this MS-based approach in the nitrilase-
catalyzed desymmetrization of a prochiral nitrile (3-hydroxyglutaryl nitrile).61 One of 
the nitrile functional groups of the substrate was labeled with 15N and the substrate 
was hydrolyzed to its respective pseudo-enantiomeric products. 
 The NMR-based approach can also be used to analyze the ee of the lipase-
catalyzed enantioselective hydrolysis of pseudo-meso-1,4-diacetoxy-2-cyclopentene 
example.59 This time, 13C isotope is used to label the prochiral compound. High-
throughput NMR analysis with up to 1400 ee determinations per day can be achieved 
via miniaturization and automation of the samples. 
 There are not many assays available for screening enantioselective reactions 
for prochiral substrates as it is easier to develop an assay to evaluate the different 
enantiomers in the product rather than the achiral substrate. 
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Assays to quantify the enantiomeric products from an enzymatic reaction 
 A general method for screening enantioselective syntheses is to analyze the ee 
of the enantiomeric products. This method is independent of the nature of the starting 
substrate used in the enzymatic reaction. 
 In a method known as EMDee (enzymatic method for determining 
enantiomeric excess),62 Abato and Seto was able to determine the enantiopurity of a 
library of chiral secondary alcohols by using an enzyme to selectively process one 
enantiomer of the product from a catalytic reaction. In the paper, diethylzinc was 
added to benzaldehyde to yield 1-phenylpropanol. The (S)-aromatic alcohol 
dehydrogenase from Thermoanaerobium sp. was then used to selectively oxidize the 
(S)-enantiomer of the alcohol. The rate of this process can be monitored by observing 
the formation of NADPH (which relates to the quantity of (S)-enantiomer present in 
the mixture) by UV/Vis spectroscopy at 340mm. Similarly, (R)-aromatic alcohol 
dehydrogenase from Lactobacillus kefir can be used to quantify the amount of (R)-
enantiomer present. About 100 samples can be processed in 30mins thus leading to 
about 4800 ee determinations per day with an accuracy of +10%. The generality of 
the EMDee assay in this case may be limited to chiral alcohols which show high 
enantioselectivity in the oxidation catalyzed by alcohol dehydrogenase. Otherwise, 
one would have to look for a different, more selective alcohol dehydrogenase. The 
assay would, of course, need to be optimized for every different chiral alcohol and its 
related enzyme. 
 Enzyme immunoassays (EIA), which is widely used in the area of biology and 
diagnosis, can also be applied in the field of chiral chemistry. Mioskowski and 
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coworkers demonstrated this new method using a 96-well microtiter plate in which 
benzoyl formic acid (BF) was reduced in the presence of organometallic catalysts into 
chiral mandelic acid (MA).63  After 14 hours, the reaction mixture was then 
transferred to two different 96-well plates: Plate 1 contained an immobilized antibody 
that binds both enantiomers of the product and can be used to determine yield; 
whereas plate 2 contained an immobilized enantiospecific antibody (with high affinity 
for (S)-MA) that can be used to determine enantioselectivity. Both reaction yield and 
ee were measured by determining the decrease in UV/Vis absorbance in their 
respective plates. The application of this immunoassay method depends on the 
availability of specific antibodies, which generally can be raised to almost any 
compound of interest. About 1000 ee determinations are possible per day with 
accuracy of about ±9%. 
 Belder, Ludwig, Wang and Reetz recently introduced a novel integrated 
approach which combines a microfluidic reactor and the microchip electrophoresis on 
a single chip.64 The hydrolytic kinetic resolution of chiral glycidyl phenyl ether, 
utilizing different epoxide hydrolase mutants from Aspergillus niger, was investigated 
as a model system. Borate buffer containing heptakis-6-sulfato-β-cyclodextrin as a 
chiral selector was utilized in the separation of the compounds into respective 
enantiomers in less than 90s. The chip prototype contains four microvials within the 
reaction part of the device, thus allowing the reaction and screening of up to three 
catalysts versus one substrate in a single set of experiment. Detection of educts and 
products was realized by deep UV native fluorescence detection. Furthermore, 
integrated chip electrophoresis allowed ee value determinations with relative standard 
deviations (RSD) of 1-3% and E values RSD of 3-21%. 
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 The examples covered in this literature review, though not exhaustive, 
illustrate a diversity of high-throughput assays that can be used to evaluate the 
enantioselectivity of enzymes. No single assay is truly universal and at times, high-
throughput is obtained by sacrificing accuracy. As the demand for enantiopure 
compounds continue to grow, the pressure to discover new bio-catalysts via directed 
evolution and rational design coupled with high-throughput screening/selection 
methods will push the advances in this field to greater heights. Progress in high-
throughput screening/selection will be measured not only in accuracy or applicability, 
but more importantly in how fast and simple the assay really is. 
1.5 Cofactor Regeneration 
 Most of enzymes which are currently applied in industry are hydrolytic in 
nature, which means that they perform relatively straight-forward cofactor-
independent chemistry.65-67 In contrast, cofactor-dependent enzymes, such as 
oxidoreductases and transferases, can perform more complex chemistry and play an 
important  role in many synthetic applications.67-72  For example, NAD-dependent 
oxidoreductases catalyze the asymmetric reduction of carbonyl groups to alcohols and 
amines72,73 and coenzyme A-dependent (CoA) synthetases catalyze asymmetric 
carbon-carbon bond formation.74-77  However, as these enzymes use expensive 
cofactors, they are rarely applied in industrial settings. 
 Low molecular weight cofactors like NAD and CoA are essential for 
numerous enzymatic reactions. Some cofactors such as pyridine dinucleotides 
(NAD(P)(H)), acetyl coenzyme A, and nucleoside triphosphates (NTPs) act more like 
cosubstrates and are loosely bound (KD values in the µM-mM range). They operate as 
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functional group transfer agents , and are consumed in stoichiometric amounts.78  
Other cofactors which are tightly bound to the enzymes such as adenosylcobalamin, 
pyridoxal phosphate, biotin, and flavins, are mostly self-regenerating.  
 The use of enzyme-cofactor reactions is limited by the high costs involved in 
the stoichiometric addition of cofactors, hence necessitating the need for an efficient 
in situ cofactor regeneration system. Various methodologies of cofactor regeneration 
have been developed including biological, enzymatical, electrochemical, chemical 
and photochemical methods.79-87 An example of a chemical method is in the 
regeneration of acetyl-CoA from CoA and (S)-acetylthiocholine iodide, in which a 
TTN of 1160 was obtained in the production of citrate.88   
 Enzymatic regenerative strategies are particularly preferred for industrial 
processes as they have several distinct advantages over their electrochemical, 
chemical, and photochemical counterparts that include high selectivity, compatibility 
with production enzymes, better stability, higher TTNs, and superior 
productivity.78,86,87  Enzymatic methods for cofactor regeneration have been described 
for oxidoreductions with NAD(P)(H),80,89-91 phosphoryl transfer reactions with 
nucleoside di- and triphosphates (NDP, NTP),92-97 glycosylations with sugar 
nucleotides,98-100 sulfuryl transfer reactions with PAPS,101,102 and acyl transfer 
reactions with acetyl-CoA.74,77,88  Many of these have been successfully implemented 
in large-scale synthesis.84,103-105 
1.5.1 NAD(P)H Regeneration 
 The reduced nicotinamide cofactors NADH and NADPH are involved in many 
biochemical oxidation and reduction reactions. Unfortunately, the high cost of these 
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cofactors and their required stoichiometric addition to a reaction is the major 
inhibitory factor for practical applications . Thus, an in situ regeneration method is 
necessary and its advantages include prevention of product inhibition by the cofactor, 
simplified reaction workup, and in some cases, a favorable influence on the reaction 
equilibrium.  Enzymatic methods are presently the preferred method for NAD(P)H 
regeneration, with the current state of the art being the formate/formate 
dehydrogenase system106 (FDH) as used on the preparative scale by Degussa for 
production of L-tert-leucine.107  The advantages of FDH regeneration system include 
the use of formate as an inexpensive, stable, innocuous substrate and the production 
of CO2 that can be easily removed from the reaction. However, disadvantages of this 
system is its low specific activity (~6 U/mg)108 and general sensitivity to organic 
solvents. 
 Although NADH regeneration by FDH has been most widely applied, other 
systems have also been developed for NAD(P)H regeneration. Noteworthy non-
enzymatic systems for NAD(P)H regeneration typically involve ruthenium or 
rhodium catalysts which transfer reducing equivalents to NAD(P)+.109-116  However, 
these methods generally suffer from catalyst or electrode fouling, or low 
productivity.111,112,114,116,117  Other enzymatic methods that have been developed 
include glucose/glucose dehydrogenase118 (GDH), glucose/glucose-6-phosphate 
dehydrogenase119 (G6PDH) and isopropanol/Pseudomonas alcohol dehydrogenases 
(ADH) for NAD(P)H regeneration. 
 The recently discovered phosphite dehydrogenase (PTDH) from Pseudomonas 
stutzeri120 may have kinetic and practical advantages for NADH regeneration.  This 
enzyme catalyzes the oxidation of phosphite to phosphate. The large change in free 
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energy of this reaction (ΔG°’ = -63.3 kJ/mol estimated from redox potentials) and the 
associated high equilibrium constant (Keq = 1 x 1011) makes PTDH a promising 
NADH regenerative enzyme.121  PTDH also displays a broad pH-rate maximum and 
the enzyme is not inhibited by phosphate, even at high concentrations.120  Although 
PTDH naturally prefers NAD+ over NADP by about 100-fold, a mutant PTDH has 
been engineered with relaxed specificity toward both nicotamide cofactors.122  In a 
recent work, a thermostable and highly active PTDH was also engineered for practical 
NAD(P)H cofactor regeneration.33,123 PTDH was also applied for NADH regeneration 
in the production of L-lactate from pyruvate by L-Lactate dehydrogenase, D-lactate 
from pyruvate by D-lactate dehydrogenase, malate from oxaloacetate by malate 
dehydrogenase, and trifluoromethanol from trifluoroacetaldehyde by an alcohol 
dehydrogenase.121 
1.6 Project Overview 
 This thesis focuses on a novel P450pyr monooxygenase from Sphingomonas 
sp. HXN-200 which belongs to the CYP153 family. CYP153 enzymes are class I 
P450 proteins, which requires the presence of an electron-delivering protein system 
(ferredoxin and ferredoxin reductase protein) to effect their monooxygenase activity 
(Figure 1.3). 
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Figure 1.3. Schematic organization of Class I P450s. The ferredoxin reductase (FdR) transfers 
electrons from NAD(P)H, via an electron shuttle ferredoxin (Fdx), to the heme center of the P450 
domain.11 
  This novel enzyme was discovered while screening 70 alkane-degrading 
strains on a microtitre plate for the 3-hydroxylation of N-benzyl pyrrolidine.124-126 A 
total of 12 alkane-degrading strains were found to be able to catalyze the 
hydroxylation of N-benzyl pyrrolidine to N-benzyl-3-hydroxypyrrolidine. While the 
well-known membrane-bound AlkB-containing Pseudomonas oleovorans GPO1 
affords the (R)-product in 52% ee, Sphingomonas sp. HXN-200 exhibits a much 
higher activity, excellent regioselectivity and the opposite enantioselectivity, giving 
the (S)-product in 53% ee. The Sphingomonas sp. HXN-200 was also found to be able 
to catalyze the highly active,  regio- and stereoselective hydroxylation of a broad 
range of substrates, including piperidines, azetidines, 2-pyrrolidinones and 2-
piperidinones.127-130 The enantiomeric products of the hydroxylation reactions are 
useful pharmaceutical intermediates which are difficult to synthesize via organic 
chemistry routes. The enzyme responsible, the P450pyr monooxygenase, was thus 
isolated from this strain.131 
 The enantioselectivity of the wild type (WT) P450pyr for the biohydroxylation 
of N-benzyl pyrrolidine to N-benzyl-3-hydroxypyrrolidine is unsatisfactory and 
therefore it is desirable to improve the P450pyr enantioselectivity via protein 
engineering. To do so, it would be necessary to first develop a high-throughput ee 
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screening assay which can be applied for asymmetric biohydroxylations. Next, we are 
also interested in engineering an efficient P450pyr system coupled with a cofactor 
regeneration to increase activity and productivity. Finally, we will focus on the partial 
characterization of cytochrome P450pyr and its enantioselective mutants that were 
previously engineered by directed evolution. 
 Chapter 2 describes the development of high-throughput screening methods 
for asymmetric biohydroxylations catalyzed by the P450pyr enzyme. Two high-
throughput methods have been developed: 1) two-enzyme-based colorimetric assay 
and 2) mass spectrometry-based method using an isotopically-labeled optically active 
substrate. The colorimetric assay was also adapted to a 96-well plate format making it 
the first example of a high-throughput enantioselectivity assay developed and used in 
the directed evolution of a monooxygenase for asymmetric biohydroxylations. 
 Chapter 3 describes the first example where directed evolution has been 
applied to improve the biohydroxylation enantioselectivity of a class I P450 
monooxygenase using a prochiral substrate. Several mutants exhibiting increased 
and/or inverted enantioselectivity were identified, with product ee of 83% (R) and 65% 
(S) for mutants 1AF4A and 11BB12, respectively. The homology modeling of the 
P450pyr and the development of an active E. coli recombinant expressing the 
P450pyr and its electron transport system have also been described. 
 Chapter 4 describes an efficient monooxygenase biocatalytic system with 
cofactor recycling which was developed by co-expressing a glucose dehydrogenase 
from Bacillus substilis or a phosphite dehydrogenase from Pseudomonas 
stutzeri together with the P450pyr system in a recombinant E. coli.  
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 In chapter 5, the wild type P450pyr and its mutants were purified and 
reconstituted with their auxiliary electron transport proteins, ferredoxin and ferredoxin 
reductase in vitro. The changes in product ee when using 1AF4 and 1AF4A mutants 
to catalyze the hydroxylations of a range of different substrates were also investigated. 
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Chapter 2 : Development of a High-throughput Enantiomeric Excess 
(ee) Screening Assay 
2.1 Introduction 
 The expanding world market for chiral fine chemicals and pharmaceuticals has 
created a great demand for enantiopure compounds. Among the various ways to 
prepare enantiopure compounds is the use of asymmetric catalysts, particularly 
biocatalysts or enzymes which are favored due to their high activity and specificity. 
This has led to the growth in two major areas: 1) the generation and expression of 
random genetic libraries in suitable host systems and 2) methods for screening or 
selecting variants of interest that possess the desired characteristic (e.g. 
enantioselectivity, activity and stability under different process conditions). Vast gene 
libraries of more than 1012 variants can now be readily prepared via molecular 
biological methods such as error-prone polymerase chain reaction (epPCR) and DNA 
shuffling. While success in identifying a hit variant has increased, the poor 
availability of practical high-throughput screening techniques for identifying active 
variants of interest is a bottleneck in these directed evolution approaches.  
 Many high-throughput methods for determining the enantioselectivity of 
enzymes have been developed,132-138 although most of these methods have been 
focused on screening for the enantioselectivity in kinetic resolutions since this can be 
done quickly by comparing the different reaction rates of the two enantiomers of the 
substrate. The determination of catalyst enantioselectivity for asymmetric 
transformations from a prochiral substrate is dependent on the measurement of 
product ee except in cases of reversible transformations where their reverse reactions 
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could be analyzed as kinetic resolutions. The most common methods for analyzing the 
product ee of asymmetric transformations are GC or HPLC with a chiral column 
which suffers from drawbacks such as a long analytic time and the required work-up 
procedure to extract the product from the aqueous reaction system. Other medium to 
high-throughput enantioselectivity analysis method include the use of GC-GC with a 
chiral column,139 HPLC with CD/UV or OR/RIU detection,140,141 chirally modified 
capillary electrophoresis,142 electrospray ionization tandem mass spectrometry 
(MS),143 color indicators based on doped liquid crystals,144 or competitive enzyme 
immunoassays.145 More complicated high-throughput methods that require the 
product to be further converted have also been developed. For example, product ee 
can be estimated by exploiting the kinetic resolution effects on the product146 using 
mass- or fluorescence-tagged quasi-enantiomeric mixtures of acylating agents with 
MS147,148 or fluorescence149 detection. When the product concentration is known, the 
product ee can be determined by using an enzyme to catalyze a further transformation 
of the product which can be detected by UV spectroscopy62 or infrared 
thermography.150 The product ee can be also established by using two enantioselective 
enzymes to modify the product with UV detection of NAD(P)H formation.151 
Nevertheless, the application of these methods in catalyst discovery is limited by 
many factors and can only be applied for certain cases only. 
 In order to screen the mutant libraries generated in our directed evolution work, 
we need to develop a practical and efficient high-throughput ee-screening assays for 
asymmetric biohydroxylations. In this chapter we will discuss two high-throughput ee 
screening assays: a two-enzyme-based colorimetric assay152 and an MS-based method 
using an isotopically-labeled optically active substrate.153   
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2.2 Two-Enzyme-Based Colorimetric ee Screening Assay 
2.2.1 Results and Discussion 
2.2.1.1 Basic Principle of the Assay 
 The development of an efficient high-throughput ee-screening method was no 
trivial task. Most of the screening/selection methods that are found in literature 
focused on improving the enantioselectivity in the kinetic resolution of the enzyme, 
and very few for asymmetric transformations due to the complexities in developing an 
ee-assay. A high-throughput two-enzyme-based colorimetric assay, adapted to a 96-
well plate format, was developed in order to semi-quantitatively determine the ee of 
the racemic product from an asymmetric biohydroxylation. The concept of utilizing 
two complementary alcohol dehydrogenases has been described,151,154 but the 
colorimetric determinations make it the first example of a high-throughput 
enantioselectivity assay developed and used in the directed evolution of a 
monooxygenase for asymmetric biohydroxylations. 
 After an extensive literature search, we found two alcohol dehydrogenases, i.e. 
BRD  from Micrococcus luteus155 and RDR  from Devosia riboflavina156 that were 
highly specific for (S)- and (R)- 1-benzyl-3- pyrrolidinol 2, respectively. The principle 
of our method is illustrated in Scheme 2.1. Enantioselective biohydroxylation of N-
benzyl pyrrolidine 1 to its corresponding products (R)- and (S)-N-benzyl-3-
hydroxypyrrolidines 2 was selected as the target reaction. This example represents an 
enantioselective hydroxylation of a non-activated carbon atom of a symmetric 
substrate with equal C-H bond at 3- and 4-position. It is also a useful 
biotransformation to prepare the corresponding products (S)- or (R)-2 which are 
important pharmaceutical intermediates.130  
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Scheme 2.1. A high-throughput two-enzyme based colorimetric ee assay for asymmetric 
biohydroxylation of prochiral substrate N-benzyl pyrrolidine 1 to its corresponding products (R)- and 
(S)-1-benzyl-3- pyrrolidinol 2. The formation of formazan corresponded to the activity of the 
dehydrogenases that in turn correlated to the concentration of each enantiomer in the aqueous solution. 
 In the presence of NADP+, the enantioselective alcohol dehydrogenase BRD 
could convert (S)-2 to 1-benzyl-3-pyrrolidinone 3 whereas in the presence of NAD+, 
the RDR could convert (R)-2 to 3. By utilizing the nitro blue tetrazolium (NBT) - 
phenazine methosulfate (PMS) colorimetric assay,122 the production of NAD(P)H was 
monitored by observing the formation of formazan at OD580. The NBT-PMS-based 
assay was chosen since it offered simplicity, reproducibility, and a high signal which 
can be measured even in the presence of whole-cells and media.122,157 In this assay, 
the NAD(P)H production was coupled to reduction of NBTox through the chemical 
mediator PMS.  Upon reduction, NBTox converts from a soluble yellow compound to 
a partially soluble purple formazan dye (NBTred). The formation of formazan 
corresponded to the activity of the dehydrogenases that in turn correlated to the 
concentration of each enantiomer in the aqueous solution. Hence, the ee of the 
BRD
RDR
ee(R) -100       -50            0           50         100
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enantiomeric mixture could be estimated from the apparent concentration of each 
enantiomer. The ee value was also found to be independent of the reaction rate of 
each alcohol dehydrogenase. 
2.2.1.2 Cloning and Expression of the Alcohol Dehydrogenases, BRD and RDR 
 The BRD gene was cloned from the M. luteus gDNA. In order to obtain a 
higher level of expression of the BRD in E. coli, the first 41 codons were optimized to 
lower the GC ratio155 without altering the amino acid sequence. The modified BRD 
gene was cloned into the NdeI and BamHI sites of the pET15b vector. The BRD was 
then expressed in E. coli BL21(DE3) and purified using a Ni-NTA gravity flow 
column (Figure 2.1). When the BRD was expressed in TB media, the purified protein 
was inactive. However, when the BRD Exp media155 was used, we managed to obtain 
an active protein. 
 
Figure 2.1. SDS-PAGE of purified N-histag BRD and N-histag RDR. 
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 The RDR could not be amplified successfully by PCR from the D. riboflavina 
gDNA. After several failed attempts, we decided to synthesize and codon optimize the 
RDR gene by Genscript Corp. (Piscataway, NJ). The sequence of the codon optimized 
RDR is given in Fig 2.2. The RDR gene was cloned into the NdeI and XhoI sites of 
the pET28a vector. As it has been codon optimized, the RDR gene was highly 
expressed in E. coli BL21(DE3) and could be easily purified using a Ni-NTA gravity 
flow column. 
 
Figure 2.2. Codon optimized sequence of the RDR gene. 
  
  1 ATGAGCCAGG ATTTCAGCGG CAAAGTGGCC TTTGTGACCG GTGGCGCGAG CGGCATTGGT 
 61 GAAGCCGTGG TGAAACAGCT GGCGGCGCGT GGTGCGAAAG TTGTGGTTGC GGATCTGAAA 
121 CTGGAAGGTG CGCAGGCCGT GGCGGATGCG GTGAAAGCGG CGGGTGGTGA AGCCGCGGCC 
181 GTGGCGGTGG ATGTGGCCAA AGCGGATCAG GTGGAAAAAG CGGTTCAGTT TGCGGTGGAT 
241 ACCTTTGGTG CGCTGCATCT GGCGGTGAAC AATGCGGGCA TTGGTGGCGC GAGCGCGCCG 
301 CTGGGTGATT ATAGCTTTGA TGATTGGCAT CGTGTGATCG ATGTGAACCT GAACAGCGTG 
361 TTTTATAGCA TGAAATATGA AATTGTTGCC ATGCTGCGCG CGGGTGGCGG CGCCATTGTG 
421 AACATGGCGA GCATTCTGGG TAGCGTGACC TTTCCGAATG CGCCGGCCTA TGTTACCGCG 
481 AAACACGGCG TGGTGGGCAT GACCAAAAGC GCCGCCGTTG ATTATGCCAA AAAAGGCATC 
541 CGCGTTACCG CGGTTGGCCC GGGCTTTATT GATACCCCGC TGCTGAGCGC CCTGCCGAAA 
601 GAAACCCTGG ATTATCTGAA AAGCGTGCAT CCGATTGGTC GCCTGGGCAC CAGCGATGAA 
661 GTGGCCGCGC TGACCGCGTT TCTGCTGAGC GATGCGGCCA GCAACATCAC CGGCAGCTAT 
721 CATCTGGTGG ATGGTGGTTA TGTGGCCCAG TAA 
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2.2.1.3 Assay Evaluation 
 Initial assay with RDR and BRD showed that they were highly specific to the 
(R)- and (S)-2 respectively in the presence of the relevant cofactors NAD(P)H. They 
showed no activity in the presence of substrate 1. To evaluate our assay, we prepared 
9 samples containing different mixtures of (R)- and (S)-2. We assayed each sample 
with purified BRD and RDR separately, coupled with the NBT-PMS assay and found 
that the ee of the sample correlated to the color intensity of the assay (Figure 2.3). 
 
Figure 2.3. Graph shows the linear correlation between y value and ee where y where 𝑦 =
ை஽ఱఴబಳೃವିை஽ఱఴబೃವೃ
ை஽ఱఴబಳೃವାை஽ఱఴబೃವೃ
. OD580BRD is linearly correlated to the (S)-2 concentration whereas OD580RDR is linearly 
correlated to the (R)-2 concentration. This experiment was carried out in triplicate. 
 
 This assay was further optimized and adapted to a 96-well plate format and 
checked for consistency. Recombinant E. coli BL21(DE3) cells, expressing wildtype 
P450pyr, ferredoxin and ferredoxin reductase, were cultured and induced in a 96-deep 
well microplate format. The cells were then used in the biohydroxylation of substrate 
1 to product 2 in the microplate. Next, the deep well plates were centrifuged and 
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aliquots (80 µL) of the supernatant containing the unreacted 1 and its racemic product 
2 were pipetted into two separate 96-well microtiter plates. In each plate, the 
concentrations of (R)- and (S)-2 could be determined using the RDR and BRD 
enzymatic reactions coupled with the NBT-PMS assay. After 2 h, the color of the 
formazan formed in each well was found to be very consistent. When measured at 
OD580 with a microplate reader, the standard deviation between wells was found to be 
~15-20%. 
2.2.2 Conclusion and Outlook 
 A simple yet high-throughput colorimetric assay based on the use of two 
enantioselective enzymes has been developed to screen the product ee of 
enantioselective hydroxylations. The color intensity of the assay correlates to the ee of 
the enantiomeric mixture, thus enabling us to quickly evaluate the enantioselectivity 
of the mixture by using a microplate reader.  
 This high-throughput ee screening assay was applied in the directed evolution 
of an enantioselective P450pyr monooxygenase which will be described further in 
Chapter 3. To date, none of the known high-throughput enantioselectivity assays in 
literature has been applied in such directed evolution experiments. Instead, the 
screening of enantioselective mutants were based mostly on activity assays158 or low 
throughput methods such as GC or HPLC analysis with a chiral column.159 Thus, this 
work is the first example of a high-throughput enantioselectivity assay developed and 
used in the directed evolution of a monooxygenase for asymmetric biotransformations.  
 The advantages of this method includes the following: a) The ee can be 
determined with satisfactory accuracy, independent of the concentration. b) The 
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enzymes do not have to be specific to, or highly active towards the alcohol. Thus, it is 
easy to find appropriate alcohol dehydrogenases for analysis of the ee value of a given 
alcohol from the large number of alcohol dehydrogenases with broad substrate ranges 
that are now available. c) The analysis method is very sensitive and can be used to 
determine the ee value of a sample with a concentration in the µM range, making it 
very useful for biocatalyst screening, where product concentration is often low. d) No 
special instruments are required as the analysis is performed with a microplate reader. 
e) The microplate reader takes only a few seconds to measure the absorbance of each 
well in a 96-well microtiter plate, thus allowing a high-throughput analysis of the ee 
values. f) The method can be extended to measure the ee values of other types of 
compounds. Two enzymes of another type may be applied, coupled with detection by 
UV spectroscopy, MS, or even HPLC or GC for short analysis times. 
2.3 Mass Spectrometry-Based High-Throughput ee Screening Assay 
(This part of the chapter was done in collaboration with Dr. Chen Yongzheng.) 
2.3.1 Results and Discussion 
 MS-based assays are known to be simple and high-throughput, and usually 
involves the use of isotopically labeled quasienantiomeric or meso substrates57,160 to 
determine the catalyst enantioselectivity. However, this approach cannot be extended 
to the asymmetric transformations of a chiral non-meso substrate. Hence, we report a 
different strategy and new principle for high-throughput ee determination for 
biohydroxylation reactions by the use of optically active, isotopically-labeled 
substrate with MS detection. The method is novel, and it allows for sensitive, accurate, 
and high-throughput measurements. 
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 To further demonstrate the generality of this method, enantioselective 
biohydroxylation of N-benzyl pyrrolidine 1 at 3-position was selected as an example. 
The principle of the method is illustrated in Scheme 2.2. An enantioselective enzyme 
which could catalyze the hydroxylation of 1 to give the (S)-2 and (R)-2 in a ratio of y 
is selected. To establish the y value and subsequently the product ee, a simplified 
approach is applied. Enantiopure (R)- and (S)-1-benzyl pyrrolidine-3-d 3 are used as 
substrates for the biohydroxylation with the same enzyme, respectively. 
Biohydroxylation of (S)-3 gives (S)-4, (R)-5, (3S, 4R)-6, and (3R, 4R)-6, while 
biohydroxylation of (R)-3 gives (S)-5, (R)-4, (3S, 4S)-6, and (3R, 4S)-6. The ratio of 
these compounds in the products depends on the enzyme enantioselectivity and the 
deuterium effect (E) on hydroxylation. (R)- and (S)-4 have an O-D bond which is 
quickly exchanged to O-H in the biotransformation medium, giving rise to (R)- and 
(S)-2, respectively, with a mass of M. All other products have a mass of M+1. The 
ratio of the intensities of M and M+1 peaks in MS can be determined, which 
corresponds to the a value in equation (3) and the b value in equation (4), respectively. 
Based on equation (5) and (6), the y and ee values can be established. 
 To prove this concept, (S)- and (R)-3 were prepared for the first time from the 
commercially available enantiopure (S)- and (R)-2 according to the routes shown in 
Scheme 2.3. SN2 substitution of (S)- and (R)-2 using PPh3/CBr4 gave (R)-7 in 99% ee 
and 56% yield and (S)-7 in 95% ee and 48% yield, respectively. Deuteration of (R)- 
and (S)-7 via SN2 substitution with lithium aluminum deuteride afforded (S)-3 in 64% 
and (R)-3 in 59% yield, respectively. The ee of 3 is expected to be the same as that of 
the corresponding precursor 7: (S)-3 in 99% ee and (R)-3 in 95% ee. 
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 To evaluate the new method, (S)-3 in 99% ee and (R)-3 in 95% ee were used, 
respectively, for the hydroxylation. Instead of GC-MS, the potential of using LC-MS 
for the analysis was explored. At first, Sphingomonas sp. HXN-200, a known 
biocatalyst for the hydroxylation of non-activated carbon atom,130 was selected as the 
catalyst. Biohydroxylation was performed with 5 mM (R)- and (S)-3, respectively, in 
a cell suspension of 5.5 g cdw/L in 5 mL 50 mM potassium phosphate buffer (pH 7.5) 
containing 2% (w/v) glucose at 30 °C for 1 h. The samples directly taken from 
aqueous biotransformation mixtures were analyzed by LC-MS, and typical LC-MS 
chromatograms are shown in Figure 2.4. No column separation was required, and the 
a and b values were easily obtained from the intensities of the signals at 178 (M) and 
179 (M+1). Thus, the y and ee values were calculated based on equation (5) and (6). 
As summarized in Table 2.1, the product ee for biohydroxylation of 1 with 
Sphingomonas sp. HXN-200 was estimated at 53% (S) with this method (Entry 1). 
The real product ee for the biohydroxylation of 1 with Sphingomonas sp. HXN-200 
under the same conditions was established as 54% (S) by chiral HPLC analysis. This 
demonstrates the high accuracy of the new method. Moreover, the new method using 
LC-MS analysis does not require the extraction of the product into organic solvent, 
allowing the direct use of aqueous samples taken from biotransformation mixtures. It 
also has high sensitivity, allowing the use of a 20× diluted sample containing 0.023 
mM product. In comparison, chiral HPLC analysis required the extraction of the 
product from aqueous medium with ethyl acetate followed by concentration of the 
sample via evaporation to 30 µL. In fact, chiral HPLC analysis failed with a non-
concentrated sample due to the sensitivity limitation. LC-MS analysis took only 1.0 
min per sample which equates to a theoretical throughput of 1440 samples per day. In 
comparison, chiral HPLC analysis required about 30 min per sample. 
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Scheme 2.2. The principle of a high-throughput enantioselectivity assay for the biohydroxylation of a 
symmetric substrate based on the use of enantiopure deuterated substrates and MS detection. 
 
 
 
Scheme 2.3. Synthesis of (R)- and (S)-1-benzyl pyrrolidine-3-d 3. 
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Figure 2.4. LC-MS analysis of the product from biohydroxylation of (R)- and (S)-3 with 
Sphingomonas sp. HXN-200, respectively. (A) and (B): Biohydroxylation of (S)-3; (A) LC 
chromatogram; (B) MS of the peak between 0.2-0.3 min in LC. (C) and (D): Biohydroxylation of (R)-3; 
(C) LC chromatogram; (D) MS of the peak between 0.2-0.3 min in LC. 
 
Table 2.1. Product ee of the biohydroxylation of 1 to 2 with different biocatalysts established by an 
LC-MS-based assay. 
Entry Biocatalysts [a] Time (h) 
Product 
concentration[b] a b y 
ee [c] 
(%) 
ee [d]
(%) 
1 Sphingomonas sp. HXN-200 1.0 0.023
 mM 0.080 0.017 3.25 53(S) 54(S) 
2 E. coli BL21(DE3) 1AF4 0.5 0.005 mM 0.049 0.179 0.372 46(R) 42(R) 
3 P. oleovorans GPo1 12 0.009 mM 0.014 0.061 0.324 51(R) 57(R) 
 
[a] Enantioselective hydroxylations of 2-5 mM (R)- and (S)-3 were performed, respectively, in 5 mL 
cell suspension (5-30 g cdw/L) of different biocatalysts at 30°C and 300 rpm. [b] Concentration refers 
to the analytic sample that has been diluted 20× from the original aqueous sample taken from 
biotransformation mixtures. [c] Determined and calculated based on LC-MS analysis using the new 
method. [d] Determined by chiral HPLC analysis of the product from biohydroxylation of 7 with 
different biocatalysts under same biotransformation conditions. The analytic sample was prepared by 
extracting the product with 5 mL ethyl acetate and concentrating via evaporation to 30 µL. Without 
concentrating the sample, it was not possible to determine the product ee due to sensitivity limitation.
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 The method was further examined with other available biocatalysts for this 
hydroxylation. Recombinant E. coli BL21(DE3) expressing 1AF4 mutant of the P450 
monooxygenase of Sphingomonas sp. HXN-200 catalyzed the biohydroxylation of 1, 
giving the corresponding (R)-2 in 42% ee. This is the opposite enantioselectivity to 
Sphingomonas sp. HXN-200. To obtain the product ee value by our new method, 
biotransformation of (R)- and (S)-3 with the mutant 1AF4 was performed under the 
same condition, respectively, and the sample from aqueous buffer was analyzed by 
LC-MS without column separation. As shown in Table 2, Entry 2, the product ee was 
established as 46% (R) by this method, which has error of only 4% ee. Also in this 
case, the ee determination is sensitive, with product concentration of 0.005 mM, and 
fast, with an analysis time of 1.0 min.  
 Pseudomonas oleovorans GPo1 contains a well-known membrane-bound 
AlkB hydroxylase system which catalyzes the hydroxylation of a number of aliphatic 
compounds.161 Biohydroxylation of 1 with this strain gave (R)-2 in 57% ee. Similarly, 
the ee value was also established by using the new method via the separate 
biotransformation of (R)- and (S)-3 with P. oleovorans GPo1 and LC-MS analysis of 
the aqueous sample. As shown in Table 2.1, Entry 3, the product ee was established as 
51% (R) by this method with an error of 6% ee. Once again, the analysis is sensitive 
and fast, and also able to analyze the sample containing 0.009 mM product within 1.0 
min. 
2.3.2 Conclusion 
 In summary, we have developed a new method for measuring the product ee 
for enantioselective hydroxylation based on the use of enantiopure deuterated 
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substrates and MS detection. Our method has several distinctive features: a) The ee 
can be determined with satisfactory accuracy, independent of the type of 
hydroxylations and the nature of biocatalysts. b) The analytic method is very sensitive. 
It can analyze samples with product concentration as low as 0.005 mM, thus being 
suitable for the screening of enzymes for biohydroxylation, where the product 
concentration is often low. c) The analysis is based on MS and does not require 
separation.  It takes only 1.0 min per sample for LC-MS analysis, enabling high-
throughput analysis of up to 1440 samples per day. d) The analytic method is simple. 
It allows for direct analysis of aqueous samples from biotransformations with no 
further reactions on the bioproduct, a step which is often necessary for many other 
assays. e) The deuterated substrate can be easily prepared from the corresponding 
alcohol. 
2.4 Materials and Methods 
2.4.1 Two-Enzyme-Based Colorimetric ee Screening Assay  
Materials 
 Escherichia coli BL21(DE3) and the expression plasmids were purchased 
from Novagen (Madison, WI). PCR grade dNTPs were obtained from Roche Applied 
Sciences (Indianapolis, IN). Restriction enzymes, Phusion High-Fidelity DNA 
polymerase, T4 DNA ligase and their corresponding buffers were purchased from 
New England Biolabs (NEB) (Beverly, MA). D-Glucose was purchased from 
ThermoFisher (Pittsburgh, PA). Ampicillin, kanamycin, isopropyl β-D-
thiogalactopyranoside (IPTG), nitro blue tetrazolium (NBT), phenazine methosulfate 
(PMS), NAD+, and NADP+ were purchased from Sigma (St. Louis, MO). Other 
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required salts and reagents were purchased from either Fisher or Sigma-Aldrich. The 
Ni-NTA agarose, QIAprep spin plasmid mini-prep kit, QIAEX II gel purification kit, 
and QIAquick PCR purification kit were purchased from Qiagen (Valencia, CA). 
Various oligonucleotide primers were obtained from Integrated DNA Technologies 
(Coralville, IA). SDS-PAGE gels, buffers and protein size markers were purchased 
from Bio-Rad (Hercules, CA). 
Cloning, Overexpression, and the Purification of the BRD Alcohol 
Dehydrogenase  
 The genomic DNA from Micrococcus luteus was extracted using the Wizard 
Genomic DNA purification kit from Promega (Madison, WI). The BRD gene was 
then PCR amplified from the genomic DNA using the following primers: BRDfwd, 
5'- TTA ACT ACT CAT ATG CGA CGG ATG ACG CTG CC -3' and BRD rev, 5'- 
TTA ACT ACT GGA TCC TTA CAG CAT TTC CAG TGG TCG CG -3'. The 
amplified gene was digested with NdeI and BamHI and ligated into the pET15b vector. 
The first 41 codons were optimized155 by digesting the pET15b-BRD using NdeI and 
XhoI and replacing it with the NdeI/XhoI digested PCR amplified fragment (5’-tta act 
CAT ATG CGT CGT ATG ACT TTA CCA TCT GGT GAA TCT ATT CCA GTT 
TTA GGT CAA GGT ACT TGG GGT TGG GGT GAA GAT CCA GGT CGT CGT 
GGT GAT GAA GTT GCT GCT TTA CAT GCT GGT CTC GAG tta act-3’, NdeI 
and XhoI restriction sites are underlined, flanking bases are in small caps). This PCR 
fragment was synthesized using overlap extension PCR of the following three 
fragments: fragfwd1 5'-TTA ACT CAT ATG CGT CGT ATG ACT TTA CCA TCT 
GGT GAA TCT ATT CCA GTT TTA GGT CA-3', fragfwd2 5'-AA GAT CCA GGT 
CGT CGT GGT GAT GAA GTT GCT GCT TTA CAT GCT GGT CTC GAG TTA 
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ACT-3', fragrev 5'-ACC ACG ACG ACC TGG ATC TTC ACC CCA CCC CAA 
GTA CCT TGA CCT AAA ACT GGA ATA GA-3'. The resulting pET15b-BRD* 
was electroporated into electrocompetent BL21(DE3) and then plated on LB plates 
containing 100 µg/mL ampicillin. The BL21(DE3) pET15b-BRD* was cultured in 5 
mL LB media overnight and then inoculated into 500 mL BRD Exp media155 (1.5% 
(w/v) glycerol, 1.5% (w/v) Bacto tryptone, 0.4% (w/v) Bacto yeast extract, 0.2% (w/v) 
sodium chloride, 0.8% (w/v) potassium dihydrogen phosphate, 0.05% (w/v) 
magnesium sulfate heptahydrate, pH 6.0). The culture was induced at OD600=0.6-0.8 
and cultured at 23°C for 18 h at 250 rpm. The cells were harvested by centrifugation 
and lysed by French press.  The BRD protein was purified using gravity flow columns 
containing 3 mL of Ni-NTA resin washed with 60 mL 10 mM imidazole buffer (50 
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0), 60 mL 20 mM imidazole 
buffer, 30 mL 30 mM imidazole buffer and 3 mL 50 mM imidazole buffer.  Proteins 
were eluted with 100 mM imidazole buffer and the protein fractions were analyzed 
using the Bradford reagent (Bio-Rad).  Proteins were concentrated using Millipore 
Amicon Ultra-4 centrifugal filter device (MWCD 10 kDa) at 4,000 rpm at 4°C, 
washed three times with 50 mM potassium phosphate buffer (pH 7.5), and 
concentrated again. Concentrated protein was stored at -80°C in 15% glycerol. 
Cloning, Overexpression and the Purification of the RDR Alcohol 
Dehydrogenase 
 The RDR gene156 from Devosia riboflavina was codon optimized and 
synthesized by Genscript Corp (Piscataway, NJ). The gene was PCR amplified further 
using forward primer RDRfwd NdeI, TTA ACT ACT CAT ATG TCC CAG GAT 
TTT TCA GGC AAG GTC (NdeI restriction site underlined) and reverse primer 
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RDRrev XhoI, TTA ACT ACT CTC GAG CTA TTG GGC GAC GTA GCC GC 
(XhoI restriction site underlined). The amplified gene was digested with NdeI and 
XhoI and ligated into the pET28a vector. The resulting construct was then 
electroporated into electrocompetent BL21(DE3) and plated on LB plates containing 
50 µg/mL kanamycin. The BL21(DE3) pET28a-RDR was cultured in 5 mL LB media 
overnight and was then inoculated into 500 mL TB media. The subsequent protein 
expression and purification steps are the same as that for the BRD alcohol 
dehydrogenase. 
Assay Evaluation 
 To measure the ee value, samples containing the two enantiomers (R)- and (S)-
2 in various ratios were prepared in microplates and separately oxidized with each of 
two enzymes, namely BRD and RDR. A mixture containing 80 µL aliquots of each 
sample, 10 µL of the diluted BRD or RDR (~1 µg of enzymes), 0.5 mM of NAD(P)+ 
as well as 10 µL of  nitro blue tetrazolium (NBT) - phenazine methosulfate (PMS) 
10× mixture (20 mg NBT and 1 mg PMS) was pipetted into individual deep wells in a 
microtiter plate. The plates were left in the dark at room temperature for 2 h. The 
formation of a soluble purple formazan was measured at OD580 in a Spectramax 
340PC microplate reader (Molecular Devices, Sunnyvale, CA). This experiment was 
conducted in triplicate. The same protocol was used to analyze the supernatant of a 
whole-cell assay.   
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2.4.2 Mass Spectrometry-Based High-Throughput ee Screening Assay 
Materials 
 All chemical reagents and solvents were purchased from Acros Organics, 
Sigma-Aldrich, Fluka, or Merck and used without further purification. N-benzyl 
pyrrolidine 1 (97%, Acros Organics), (R)-1-benzylpyrrolidine-3-ol 2 (97% ee, Sigma-
Aldrich), (S)-1-benzylpyrrolidine-3-ol 2 (99% ee, Sigma-Aldrich), pyridine (99.9%, 
Sigma-Aldrich), POBr3 (98.5%, Fluka), THF (99.9%, Sigma-Aldrich), pentane 
(99.9%, Sigma-Aldrich), CBr4  (99%, Sigma-Aldrich), PPh3 (99%, Sigma-Aldrich), 
CH2Cl2 (Fisher Scientific, AR grade), LiAlD4 (98% D, Sigma-Aldrich). 
Analytical Methods 
 The ee values of products were determined using a ShimadzuTM Prominence 
HPLC on a DaicelTM OB-H chiral column (250×4.6 mm, 5 μm) at 25 °C with a flow 
rate of 1 mL/min and UV detection at 210 nm. Retention time: 17.137 min for (R)-2 
and 26.856 min for (S)-2 (OB-H column, 2% isopropanol:98% n-hexane); 5.834 min 
for (R)-7 and 6.489 min for (S)-7 (OB-H column, 2% isopropanol:98% n-hexane). 
 GC-MS spectra were obtained using Agilent GC-MSD system 6890-5973A 
with GC-MSD HP-5 MS column (analytical conditions: Tc = 160°C). LC-MS spectra 
were obtained using Brucker UPLC-microTOF Q MS. Analytical conditions: positive 
mode, 4 bar nebulizing gas, 4.9 kV spray voltage, drying gas flow 8 L/min, drying gas 
temperature 200 °C. 
 1H and 13C NMR spectra were recorded on a Brucker-500 (500/75 MHz) 
spectrometer using CDCl3 as a solvent and TMS as an internal standard.  
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 Optical rotations were measured in specified solution in a 0.1 dm cell at 20 °C 
with a Perkin-Elmer 341 Polari meter.  
 Column chromatography was performed with Merck silica gel 60 (200–300 
mesh) as column material. TLC analyses were carried out with precoated Silica Gel 
60 F254 TLC-plate and the compounds were visualized with UV light.  
Synthesis of (R)- and (S)-1-Benzyl pyrrolidine-3-d 3. 
Synthesis of (R)-1-benzyl-3-bromopyrrolidine 7 
 CBr4 (4.96 g, 15 mmol) was added to a stirred solution of (S)-1-
benzylpyrrolidin-3-ol 2 (1.77 g, 10 mmol) in anhydrous CH2Cl2 (20 mL), and the 
reaction mixture was stirred for 5 min at -20 oC. PPh3 (15 mmol, 3.93 g) was added 
slowly over a timeframe of 20 min, and the temperature was slowly increased to room 
temperature (RT).  Then, the reaction mixture was continuously stirred at RT for 7h. 
The solvent was evaporated, and the crude product was purified by chromatography 
on a silica gel column (Rf = 0.2, n-Hexane/CH2Cl2/EtOAc of 100:10:5). 1.36 g (R)-1-
benzyl-3-bromopyrrolidine 7 was obtained (Purity: 99%, HPLC). Yield: 56%. 1H 
NMR (CDCl3, 500 MHz): δ= 7.238-7.336 (5H, m, Ar-H), 4.378 (1H, m, CHBr), 
3.656-3.709 (2H, t, CH2Ph), 3.164-3.199, 2.848-2.880 (2H, t, J= 6 Hz, NCH2CH), 
2.664-2.692), 2.698-2.736, 2.527-2.484, (2H, t, J= 7.5 Hz, Ha, Hc), 2.707-
2.664,2.206-2.250 (2H, m, Hb, Hd); 13C NMR: (CDCl3, 75 MHz): δ= 138.6, 128.7, 
128.3, 127.1, 63.7, 59.9, 52.7, 45.7, 36.4, 29.7; [α]D20= -19.6 (c = 1.38, CH2Cl2); ee = 
99% (R). 
 
51 
 
Synthesis of (S)-1-benzyl pyrrolidine-3-d 3 
 LiAlD4 (420 mg, 10 mmol) was added to a stirred solution of (R)-1-benzyl-3-
bromopyrrolidine 7 (1.2 g, 5 mmol) in anhydrous THF (10 mL),. The mixture was 
stirred for 10 hours at 50 oC. Upon completion of reaction, 1 mL of aq NaOH (1 M) 
was added dropwise, followed by the addition of 3 mL of water. The product was 
extracted with pentane (2 × 50 mL). The organic phase was separated, dried with 
anhydrous MgSO4, filtered, and concentrated by evaporation. After flash 
chromatography on a silica gel column (Rf = 0.2, CH2Cl2: MeOH = 100: 2), 0.47 g 
(S)-3 was isolated as a colorless liquid (Purity: 99%, HPLC). Yield: 59%. 1H NMR 
(CDCl3, 500 MHz): δ= 7.223-7.342 (5H, m, Ar-H), 3.615 (2H, s, CH2Ph), 2.507 (4H, 
t, J= 6.5 Hz, NCH2), 1.746-1.795 (3H, m, BrCHCH2CH2); 13C NMR: (CDCl3, 75 
MHz): δ= 139.35, 128.9, 128.2, 126.8, 60.7, 54.1, 54.0, 23.3, 23.1. 
Synthesis of (S)-1-benzyl-3-bromopyrrolidine 7 
 CBr4 (4.96 g, 15 mmol) was added to a stirred solution of (R)-1-
benzylpyrrolidin-3-ol 2 (1.77 g, 10 mmol) in anhydrous CH2Cl2 (20 mL), and the 
reaction mixture was stirred for 5 min at -20 oC. PPh3 (15 mmol, 3.93 g) was added 
slowly over a timeframe of 20 min, and the temperature was slowly increased to RT.  
Then, the reaction mixture was stirred continuously at RT for 7h. The solvent was 
evaporated and the crude product was purified by column chromatography on silica 
gel (Rf = 0.2, n-hexane/CH2Cl2/EtOAc ＝ 100:10:5). 1.15 g (S)-1-benzyl-3-
bromopyrrolidine 7 was obtained (Purity: 99%, HPLC). Yield: 48%. 1H NMR (CDCl3, 
500 MHz): δ= 7.247-7.328 (5H, m, Ar-H), 4.355-4.402 (1H, m, CHBr), 3.658-3.737 
(2H, t, CH2Ph), 3.167-3.201, 2.849-2.881 (2H, t, J= 6 Hz, NCH2CH), 2.738-2.787, 
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2.485-2.544, (2H, t, J= 7.5 Hz, Ha, Hc), 2.711-2.667,2.206-2.251 (2H, m, Hb, Hd); 13C 
NMR: (CDCl3, 75 MHz): δ= 138.5, 128.7, 128.3, 127.1, 63.6, 59.9, 52.7, 45.7, 36.4, 
29.7.; [α]d20= = +18.5 (c = 1.35, CH2Cl2); ee = 95% (S). 
Synthesis of (R)-1-benzyl pyrrolidine-3-d 3 
 LiAlD4 (420 mg, 10 mmol) was added to a stirred solution of (S)-1-benzyl-3-
bromopyrrolidine 7 (1.2 g, 5 mmol) in anhydrous THF (10mL). The reaction mixture 
was stirred for 10 hours at 50 oC. Upon completion of reaction, 1 mL of aq NaOH (1 
M) was added dropwise, followed by the addition of 3 mL of water. The product was 
extracted with pentane (2 × 50 mL). The organic phase was separated, dried with 
anhydrous MgSO4, and concentrated by evaporation. After flash chromatography on a 
silica gel column (Rf = 0.2, CH2Cl2: MeOH = 100: 2), 0.51 g (R)-9 was isolated as a 
colorless liquid (Purity: 99%, HPLC). Yield: 64%. 1H NMR (CDCl3, 500 MHz): δ= 
7.223-7.342 (5H, m, Ar-H), 3.614 (2H, s, CH2Ph), 2.506 (4H, t, J=6.5 Hz, NCH2), 
1.745-1.803, (3H, m, BrCHCH2CH2); 13C NMR: (CDCl3, 75 MHz): δ= 139.4, 128.9, 
128.2, 126.7, 60.8, 54.2, 54.1, 23.8, 23.1. 
Biotransformation of 1, (R)- and (S)-3 with Different Biocatalysts. 
Biotransformation of 1, R-3, S-3 with Sphingomonas sp. HXN-200 
 The cells of Sphingomonas sp. HXN-200 were cultured in E2 medium with n-
octane as carbon source130. Frozen/thawed cells of Sphingomonas sp. HXN-200 were 
resuspended into 5 mL of 50 mM potassium phosphate buffer (pH 7.5) containing 2% 
(w/v) glucose to a cell density of 5.5 g cdw/L in a 50 mL Erlenmeyer flask. 5 mM 1, 
(R)- and (S)-3 were added, respectively, into different flasks. The mixtures were 
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shaken at 30 °C and 250 rpm for 1 h. For hydroxylation of substrate 1, the cells were 
removed from the bioconversion mixture by centrifugation, and the supernatant was 
adjusted to pH 11-12 by addition of KOH followed by extraction of the hydroxylation 
product with ethyl acetate. The organic phase was separated, dried over anhydrous 
MgSO4, and removed by evaporation. The bioproduct was re-dissolved in 0.3 mL 
isopropanol for chiral HPLC analysis. Product ee was 54% (S). For hydroxylation of 
(R)-3 and (S)-3, the cells were first removed by centrifugation. Then, 50 μL of the 
supernatant was diluted 20 times with methanol and used as sample for LC-MS 
analysis. 
Biotransformation of 1, (R)-3, (S)-3 with 1AF4 mutant 
 The 1AF4 mutant was streaked on an LB agar plate containing 100 µg/mL 
ampicillin and 50 µg/mL kanamycin, and was incubated overnight at 37 ºC. A single 
colony of the 1AF4 mutant was inoculated into 5 mL of LB medium with 100 µg/mL 
ampicillin and 50 µg/mL kanamycin, and cultured overnight at 37 ºC. 500 µL of the 
overnight culture was added into 50 mL of TB medium containing 100 µg/mL 
ampicillin and 50 µg/mL kanamycin, and was shaken at 250 rpm, 37 ºC for 2 h. When 
OD600 reached 0.6-0.8, the culture was induced with 0.5 mM IPTG and shaken at 250 
rpm, 30 ºC for another 5 h. The cells were finally harvested at OD600 ~ 4. 
 In parallel experiments, the freshly harvested cells were resuspended in 50 
mM potassium phosphate buffer (pH 7.5) containing 2% (w/v) glucose to a cell 
density of 10 g cdw/L in a 100 mL Erlenmeyer flask. 2 mM of 1, (R)- and (S)-3 were 
added, respectively, into different flasks. The biotransformations were performed at 
30 °C, 250 rpm for 12 h. For hydroxylation of substrate 1, the cells were removed 
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from the bioconversion mixture by centrifugation, and the supernatant was adjusted to 
pH 11-12 by addition of KOH followed by extraction with ethyl acetate. The organic 
phase was separated, dried over MgSO4, and removed by evaporation. The bioproduct 
was dissolved in 0.3 mL CH3OH for chiral HPLC analysis. Product ee was 42%(R). 
For hydroxylation of (R)- and (S)-3, the cells were first removed by centrifugation. 
Then, 50 μL of the supernatant was diluted 20 times with methanol and used as 
sample for LC-MS analysis. 
Biotransformation of 1, (R)-3, (S)-3 with P. oleovorans GPo1 
 P. oleovorans GPo1 was grown on E2-agar plate and then inoculated into 5 
mL LB medium in a 28 mL glass bottle with a screw cap. The culture was shaken at 
30 ºC and 300 rpm for 7 h and then added to 100 mL E2 liquid medium containing 
trace elements in a 250-mL shaking flask with ventilated plastic stopper to reach an 
initial cell density of 0.1 g cdw/L. 15 mL of plastic tube containing 1 mL octane was 
put into the flask, and the vapor of toluene was used as the carbon source. The culture 
was incubated at 30 ºC and 300 rpm for 24 h (OD450 = 2.7). 
 In parallel experiments, cells of P. oleovorans GPo1 were suspended in 5 mL 
of 50 mM KH2PO4-K2HPO4 buffer (pH 7.5) to a density of 30 g cdw/L. 2 mM of 1, 
(R)-3 and (S)-3 were added, respectively, to individual cell suspensions. The mixture 
was shaken at 30 °C and 300 rpm for 0.5 h. For hydroxylation of substrate 1, the cells 
were removed from the bioconversion mixture by centrifugation, and the supernatant 
was adjusted to pH 11-12 by addition of KOH followed by extraction with ethyl 
acetate. The organic phase was separated, dried over MgSO4, and removed by 
evaporation. The bioproduct was re-dissolved in 0.3 mL CH3OH for chiral-HPLC 
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analysis. Product ee was 57% (R). For the hydroxylation of (R)-3 and (S)-3, the cells 
were first removed by centrifugation. Then, 50 μL of the supernatant was diluted 20 
times with methanol and used as sample for LC-MS analysis. 
Example of ee determination with LC-MS. 
 The samples were analyzed by Brucker UPLC-microTOF Q MS (Analytical 
conditions: positive mode, 4 bar nebulizing gas, 4.9 kV spray voltage, drying gas flow 
8 L/min, drying gas temperature 200 °C). As for the product 2 (C11H15NO), [M+1]/[M] 
is 12% due to the existence of 13C. 
a) For Entry 1, Table 2.1, the LC-MS spectra were shown in Figure 2.5 and 2.6. 
   From Figure 2.5:  [M] = 1011      [M+1] = 59536  
   a = [M]/[M+1] = Ey/(y+2)        a = [M]/[M+1] = 1011/(59536-12%×1011) = 0.080   
   From Figure 2.6:  [M] = 4233      [M+1] = 53684  
   b = [M]/[M+1]= E/(2y+1)         b = [M]/[M+1] = 4233/(53684-12%×4233) = 0.017   
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b) For Entry 2, Table 2.1, the LC-MS spectra were shown in Figure 2.7 and 2.8. 
   From Figure 2.7:  [M] = 62      [M+1] = 354  
   a = [M]/[M+1] = Ey/(y+2)        a = [M]/[M+1] = 62/(354-12%×62) = 0.049   
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   From Figure 2.8:  [M] = 19.5     [M+1] = 400  
   b = [M]/[M+1]= E/(2y+1)        b = [M]/[M+1] = 4233/(53684-12%×4233) = 0.179   
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c) For Entry 3, Table 2.1, the LC-MS spectra were shown in Figure 2.9 and 2.10. 
   From Figure 2.9:  [M] = 62       [M+1] = 1024  
   a = [M]/[M+1] = Ey/(y+2)        a = [M]/[M+1] = 62/(1024-12%×62) = 0.014  
    From Figure 2.10:  [M] = 27.5      [M+1] = 1987  
   b = [M]/[M+1]= E/(2y+1)         b = [M]/[M+1] = 27.5/(1987-12%×27.5) = 0.061  
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GC-MS and LC-MS spectra (Figure 2.5-2.10) 
Figure 2.5. LC-MS chromatogram of biohydroxylation (S)-3 with Sphingomonas sp. HXN-200. 
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Figure 2.6. LC-MS chromatogram of biohydroxylation (R)-3 with Sphingomonas sp. HXN-200. 
 
 
 
 
59 
 
Figure 2.7. LC-MS chromatogram of biohydroxylation (S)-3 with 1AF4 
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Figure 2.8. LC-MS chromatogram of biohydroxylation (R)-3 with 1AF4 
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Figure 2.9. LC-MS chromatogram of biohydroxylation (S)-3 with P. oleovorans GPo1 
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Figure 2.10. LC-MS chromatogram of biohydroxylation (R)-3 with P. oleovorans GPo1 
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Chapter 3 : Inverting the Enantioselectivity of P450pyr 
Monooxygenase by Directed Evolution 
3.1 Introduction 
 Enantioselective hydroxylation of non-activated carbon atoms represents a 
significant challenge in classical organic chemistry.9 However, nature has offered 
us a solution via biocatalysis with monooxygenases using molecular oxygen as 
oxidant. Cytochrome P450 monooxygenases (also known as CYP) constitute the 
largest family of heme-containing monooxygenases that can oxidize a broad range 
of substrates, often at non-reactive carbon centers.151 Of particular interest is a 
novel P450pyr enzyme from Sphingomonas sp. HXN-200126 that belongs to the 
class I P450 proteins and requires the presence of an electron-delivering protein 
system (i.e. ferredoxin and ferredoxin reductase) to effect its monooxygenase 
activity. The P450pyr monooxygenase was found to catalyze the regio- and 
stereoselective hydroxylation of non-activated carbon atom with broad substrate 
range, high activity, excellent regioselectivity, and good to excellent 
enantioselectivity. It was able to catalyze the hydroxylations of N-substituted 
pyrrolidines, piperidines, azetidines, 2-pyrrolidinones and 2-piperidinones.127-130 
The hydroxylation enantiomeric products such as (R)- and (S)-3-
hydroxypyrrolidines, (S)-4-hydroxy-pyrrolidin-2-ones, 4-hydroxypiperidines, and 
2-hydroxyazetidines are useful pharmaceutical intermediates which are difficult to 
synthesize via organic chemistry routes. 
 We are particularly interested in the enzymatic hydroxylation of N-benzyl 
pyrrolidine 1 to its corresponding (R)- and (S)-N-benzyl-3-hydroxypyrrolidines 2. 
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The (R)- and (S)-N-protected 3-hydroxypyrrolidines are interesting pharmaceutical 
intermediates. The (S)-enantiomers are used in the synthesis of calcium antagonist 
Barnidipine 3, an agent for irritable bowel syndrome, Darifenacin 4, and 
anticoagulant DX-9065a 5 (Figure 3.1). The (R)-enantiomers are intermediates for 
the preparation of carbapenem antibiotics RS-533 6 and antibacterial drug ABT-
719 7. Also, the racemic 3-hydroxypyrrolidines are useful intermediates in the 
synthesis of antibacterial drugs Tosuxacin 8 and Clinafloxacin 9.126 Unfortunately, 
the enantioselectivity of the wild type (WT) P450pyr is unsatisfactory and 
therefore it is desirable to improve the P450pyr enantioselectivity via protein 
engineering. 
 
Figure 3.1. Applications of (R)- and (S)-N-protected 3-hydroxypyrrolidines. 
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 Directed evolution, has recently emerged as a powerful approach for 
engineering biocatalysts.162-165  As discussed in Chapter 1, this in vitro method mimics 
the Darwinian evolution and involves creation of genetic diversity followed by 
screening/selection for those variants with desired features. Directed evolution and 
rational design have been used to enhance the enantioselectivity of enzymes, such as 
lipases, esterases, hydantoinases, nitrilases, epoxide hydroxylases, phosphotriesterases, 
aminotransferases, aldolases, cyclohexanone and cyclopentanone monooxygenases, 
and monoamine oxidases.159 Previous directed evolution studies on P450 
monooxygenases have focused  on altering their catalytic efficiency,43,166 substrate 
specificity,44 regioselectivity,45 solvent tolerance,46 and thermostability.47 There have 
also been many successful attempts to engineer an enzyme for the reversal in 
enantioselectivity,167-172 but none of these studies were done with the P450 
monooxygenases and very few on asymmetric catalysis. While screening a library of  
self-sufficient P450 BM-3 mutants for changes in regioselectivity, Arnold and 
coworkers have also identified some mutants with altered enantioselectivity based on 
an activity assay.158 Here, we report the first example where directed evolution, 
coupled with a high-throughput enantioselectivity screening system, has been applied 
to improve the biohydroxylation enantioselectivity of a class I P450 monooxygenase 
using a prochiral substrate. 
3.2 Results 
3.2.1 Homology Modeling 
 A protein sequence BLAST search was performed against the Protein Data 
Bank (PDB) and seven sequences were chosen from the highest scoring results. They 
were cytochrome P450terp (1CPT) from Pseudomonas sp., CYP119 from Sulfolobus 
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solfactaricus (1F4T), P450nor (1XQD) from  Fusarium oxysporum, P450st from 
Sulfolobus tokodaii (1UE8), P450epok (1PKF) from Sorangium cellulosum, 
CYP158A2 from Streptomyces Coelicolor (1S1F), and P450cam (1K2O) from 
Pseudomonas putida which share 24-29% sequence identity with P450pyr. In Figure 
3.2, the sequence alignment of these proteins with P450pyr is displayed with the 
conserved residue highlighted in blue.    
Consensus key  
*  -  single, fully conserved residue 
:  -  conservation of strong groups 
.  -  conservation of weak groups 
   -  no consensus 
 
P450pyr             MEHTGQSAAATMPLDSIDVSIPELFYNDSVGEYFKRLRKDDPVHYCADS-AFGPYWSITK 
P450st_1UE8         -----------------------------MYDWFKQMRKESPVYYDGK------VWNLFK 
CYP119_1F4T         -----------------------------MYDWFSEMRKKDPVYYDGN------IWQVFS 
P450epok_1PKF       --MTQEQANQSETKPAFDFKPFAPGYAEDPFPAIERLREATPIFYWDE----GRSWVLTR 
CYP158A2_1S1F       ----MTEETISQAVPPVRDWPAVDLPGSDFDPVLTELMREGPVTRISLPNGEGWAWLVTR 
P450nor_1XQD        ------------MASGAPSFPFSRASGPEPPAEFAKLRATNPVSQVKLFDG-SLAWLVTK 
P450terp_1CPT       ---MDARATIPEHIARTVILPQGYADDEVIYPAFKWLRDEQPLAMAHIEG-YDPMWIATK 
P450cam_1K2O        --MTTETIQSNANLAPLPPHVPEHLVFDFDMYNPSNLSAGVQEAWAVLQESNVPDLVWTR 
                                                        :                        
 
P450pyr             YNDIMHVDTNHDIFSSDAGYGGIIIDDG-IQKGGDGGLDLPN---FIAMDRPRHDEQRKA 
P450st_1UE8         YEDCKMVLNDHKRFSSNLTGYNDKLEM---LRSGKVFFDIPTRYTMLTSDPPLHDELRNL 
CYP119_1F4T         YRYTKEVLNNFSKFSSDLTGYHERLED---LRNGKIRFDIPTRYTMLTSDPPLHDELRSM 
P450epok_1PKF       YHDVSAVFRD-ERFAVSREEWESSAEY----SSAIPELSDMKKYGLFGLPPEDHARVRKL 
CYP158A2_1S1F       HDDVRLVTND-PRFGR-----EAVMDR---QVTRLAPHFIPARGAVGFLDPPDHTRLRRS 
P450nor_1XQD        HKDVCFVATS-EKLSKVRTRQGFPELG------AGGKQAAKAKPTFVDMDPPEHMHQRSM 
P450terp_1CPT       HADVMQIGKQPGLFSNAEGSEILYDQNNEAFMRSISGGCPHVIDSLTSMDPPTHTAYRGL 
P450cam_1K2O        CNGGHWIATRGQLIREAYEDYRHFSSECP---FIPREAGEAYDFIPTSMDPPEQRQFRAL 
                          :      :                                       :   *   
 
P450pyr             VSPIVAPANLAALEGTIRERVSKTLDGLP----VGEEFDWVDRVSIEITTQMLATLFDFP 
P450st_1UE8         TADAFNPSNLP--VDFVREVTVKLLSELD------EEFDVIESFAIPLPILVISKMLGIN 
CYP119_1F4T         SADIFSPQKLQTLETFIRETTRSLLDSID----P-REDDIVKKLAVPLPIIVISKILGLP 
P450epok_1PKF       VNPSFTSRAIDLLRAEIQRTVDQLLDARS----GQEEFDVVRDYAEGIPMRAISALLKVP 
CYP158A2_1S1F       VAAAFTARGVERVRERSRGMLDELVDAMLR---AGPPADLTEAVLSPFPIAVICELMGVP 
P450nor_1XQD        VEPTFTPEAVKNLQPYIQRTVDDLLEQMKQKGCANGPVDLVKEFALPVPSYIIYTLLGVP 
P450terp_1CPT       TLNWFQPASIRKLEENIRRIAQASVQRLLD---FDGECDFMTDCALYYPLHVVMTALGVP 
P450cam_1K2O        ANQVVGMPVVDKLENRIQELACSLIESLRP----QGQCNFTEDYAEPFPIRIFMLLAGLP 
                        .    :       :      :.            :         .   .     .  
 
P450pyr             FEERRKLTRWSDVTTAAPG-GGVVESWDQRKTELLECAAY----FQVLWNERVNKDPGND 
P450st_1UE8         P-DVKKVKDWSDLVALRLGRADEIFSIGRKYLELISFSK-----------KELDSRKGKE 
CYP119_1F4T         IEDKEKFKEWSDLVAFRLGKPGEIFELGKKYLELIGYVK-----------DHLNS--GTE 
P450epok_1PKF       AECDEKFRRFGSATARALG-VGLVPRVDEETKTLVASVTEGLALLHGVLDERRRNPLEND 
CYP158A2_1S1F       ATDRHSMHTWTQLILSSSHGAEVSERAKNEMNAYFSDLIG-----------LRSDSAGED 
P450nor_1XQD        FNDLEYLTQQNAIRTNGSSTARQASAANQELLDYLAILVE-----------QRLVEPKDD 
P450terp_1CPT       EDDEPLMLKLTQDFFGVEAARRFHETIATFYDYFNGFTVD------------RRSCPKDD 
P450cam_1K2O        EEDIPHLKYLTDQMTRPDGSMTFAEAKEALYDYLIPIIEQ------------RRQKPGTD 
                          .                                                    : 
 
P450pyr             LISMLAHSPATR-NMTPEEYLGNVLLLIVGGNDTTRNSMTGGVLALHKNPDQFAKLKANP 
P450st_1UE8         IVDLTGKIANS--NLSELEKEGYFILLMIAGNETTTNLIGNAIEDFTLYN-SWDYVRE-K 
CYP119_1F4T         VVS---RVVNS--NLSDIEKLGYIILLLIAGNETTTNLISNSVIDFTRFN-LWQRIRE-E 
P450epok_1PKF       VLTMLLQAEADGSRLSTKELVALVGAIIAAGTDTTIYLIAFAVLNLLRSPEALELVKAEP 
CYP158A2_1S1F       VTSLLGAAVGRD-EITLSEAVGLAVLLQIGG-EAVTNNSGQMFHLLLSRPELAERLRSEP 
P450nor_1XQD        IISKLCTEQVKPGNIDKSDAVQIAFLLLVAGNATMVNMIALGVATLAQHPDQLAQLKANP 
P450terp_1CPT       VMSLLANSKLDGNYIDDKYINAYYVAIATAGHDTTSSSSGGAIIGLSRNPEQLALAKSDP 
P450cam_1K2O        AISIVANGQVNGRPITSDEAKRMCGLLLVGGLDTVVNFLSFSMEFLAKSPEHRQELIERP 
                                  :           :  .*  :        .  :               
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P450pyr             ALVETMVPEIIRWQTPLAH--MRRTAIADSELGGKTIRKGDKVVMWYYSGNRDDEVIDRP 
P450st_1UE8         G-ALKAVEEALRFSPPVMR--TIRVTKEKVKIRDQVIDEGELVRVWIASANRDEEVFKDP 
CYP119_1F4T         NLYLKAIEEALRYSPPVMR--TVRKTKERVKLGDQTIEEGEYVRVWIASANRDEEVFHDG 
P450epok_1PKF       GLMRNALDEVLRFENILRIG-TVRFARQDLEYCGASIKKGEMVFLLIPSALRDGTVFSRP 
CYP158A2_1S1F       EIRPRAIDELLRWIPHRNAVGLSRIALEDVEIKGVRIRAGDAVYVSYLAANRDPEVFPDP 
P450nor_1XQD        SLAPQFVEELCRYHTASALA-IKRTAKEDVMIGDKLVRANEGIIASNQSANRDEEVFENP 
P450terp_1CPT       ALIPRLVDEAVRWTAPVKS--FMRTALADTEVRGQNIKRGDRIMLSYPSANRDEEVFSNP 
P450cam_1K2O        ERIPAACEELLRRFSLVADG---RILTSDYEFHGVQLKKGDQILLPQMLSGLDERENACP 
                            *  *           *         .  :  .: :      .  *        
 
P450pyr             EEFIIDRP-RPRQHLSFGFGIHRCVGNRLAEMQLRILWEEILTRFSRIEVMAEPERV--- 
P450st_1UE8         DSFIPDR--TPNPHLSFGSGIHLCLGAPLARLEARIALEEFAKKFRVKEIVKK-EKI--- 
CYP119_1F4T         EKFIPDR--NPNPHLSFGSGIHLCLGAPLARLEARIAIEEFSKRFRHIEILDT-EKV--- 
P450epok_1PKF       DVFDVRR--DTSASLAYGRGPHVCPGVSLARLEAEIAVGTIFRRFPEMKLKETPVFG--- 
CYP158A2_1S1F       DRIDFER--SPNPHVSFGFGPHYCPGGMLARLESELLVDAVLDRVPGLKLAVAPEDVPFK 
P450nor_1XQD        DEFNMNRKWPPQDPLGFGFGDHRCIAEHLAKAELTTVFSTLYQKFPDLKVAVPLGKINYT 
P450terp_1CPT       DEFDITR--FPNRHLGFGWGAHMCLGQHLAKLEMKIFFEELLPKLKSVELSGPPRLV--- 
P450cam_1K2O        MHVDFSR--QKVSHTTFGHGSHLCLGQHLARREIIVTLKEWLTRIPDFSIAPGAQIQH-- 
                      .   *         :* * * * .  **. :          :.   .:           
 
P450pyr             RSNFVRGYAKMMVRVHA------ 
P450st_1UE8         DNEVLNGYRKLVVRVERT----- 
CYP119_1F4T         PNEVLNGYKRLVVRLKSNE---- 
P450epok_1PKF       YHPAFRNIESLNVILKPSKAG-- 
CYP158A2_1S1F       KGALIRGPEALPVTWHA------ 
P450nor_1XQD        PLNRDVGIVDLPVIF-------- 
P450terp_1CPT       ATNFVGGPKNVPIRFTKA----- 
P450cam_1K2O        KSGIVSGVQALPLVWDPATTKAV 
 
Figure 3.2. Partial sequence alignment of P450pyr with members of the P450 family. PDB 
identification number (% identity with P450pyr, GenInfo Identifier (GI) number): P450st_1UE8 (29%, 
51247807), CYP119_1F4T (29%, 11514364), P450epok_1PKF (27%, 38492829), CYP158A2_1S1F 
(27%, 60593455), P450nor_1XQD (29%, 56554668), P450terp_1CPT (29%, 493949), 
P450cam_1K2O (24%, 16975144). 
 
 
Figure 3.3. Clustal W dendrogram of P450pyr with other members of the P450 family. 
  
 Since CYP119 from Sulfolobus solfactaricus (1F4T) and P450st from 
Sulfolobus tokodaii (1UE8) shared the highest homology with P450pyr (Figure 3.3), 
they were used as templates to build a homology model for P450pyr using Insight II 
software (Insight II, version 2000, Accelrys Inc., San Diego, CA). Using ProStat 
(Insight II, default parameters), the phi and psi angles were determined to be 82.4% 
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within their expected values which were comparable to 86.8% and 83.3% for identical 
analysis of the template PDB structures 1F4T and 1UE8, respectively. A value of 79.9% 
correct self-compatibility of amino acids with the modeled structure was obtained 
when inspected by Profiles-3D (Insight II, default parameters). Therefore, the model 
seemed reasonably well constructed despite the low homology with the templates.  N-
benzyl pyrrolidine 1 was manually docked using the Molecular Operating 
Environment (MOE, Chemical Computing Group Inc., Montreal, Canada) into the 
created model and the whole structure was subjected to energy minimization to 
relieve steric and torsional artifacts from the modeling and docking processes.  
 Comparison of the P450pyr homology model with X-ray structures of other 
P450s (Figure 3.4) revealed that all of these P450s have similar conserved “core 
structures.” Two access channels to the catalytic heme site were observed from the 
surface of the protein (Figure 3.5). The large cavity of the P450pyr active site 
afforded the possibility for the binding of substrate with bulky protecting groups and 
contributes to the broad substrate range of this enzyme. The enlarged heme pocket 
also shows that the ferric ion is located at the corner of the heme pocket. This may 
contribute the high regioselectivity exhibited in the hydroxylation of N-heterocyclic 
substrates with P450pyr. Within 5Å of the active site are highly conserved residues 
Thr259, Gly256, and Leu252. The residues Leu251, Leu252, Phe403, and Val404 
exhibit a hydrophobic area whereas the polar Gly255 and Gly256 may contribute to 
inducing the orientation of the hydrophilic group in the substrate. 
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relative completeness and availability of its genetic information. Initially, we cloned 
the genes encoding the P450pyr, Fdx, and FdR into different Duet expression vectors 
(i.e. pACYCDuet, pETDuet and pRSFDuet) and utilized a whole-cell assay approach 
to determine the substrate conversion percentage of each construct (Table 3.1).  The 
recombinant E. coli BL21(DE3) strain containing a dual plasmid system (pRSFDuet 
P450pyr and pETDuet Fdx FdR; Figure 3.6) showed the highest hydroxylation 
activity and was thus designated as the parent strain. The balance between the 
expression level of P450pyr and the Fdx and FdR genes plays an important role in 
determining the activity. A clear band at 48 kDa indicating the P450pyr enzyme was 
observed on an SDS-PAGE gel of the cell extract of the parent strain (Figure 3.7). 
 
  
Figure 3.6. pRSFDuet P450pyr and pETDuet Fdx FdR expression vector. The P450pyr gene was 
cloned into the NcoI/KpnI site of pRSFDuet (left vector) whereas the ferredoxin Fdx gene and the 
ferredoxin reductase FdR gene was cloned into the NcoI/AflII site (MCS1) and NdeI/KpnI site (MCS2) 
of pETDuet (right vector), respectively. These two plasmids were then transformed into BL21(DE3). 
 
 
 
pRSFDuet P450pyr
4803 bp
Kan
lacI P450pyr
T7 Promoter
lacO
RBS-1
RSF ori
T7 Terminator
KpnI (1327)
NcoI (70)
NdeI (982)
pETDuet Fdx FdR
6879 bp
lacI
Ap
Fdx
FdR
T7 promoter
T7 promoter
RBS-1
RBS
f1 ori
ColE1, pBR322 ori
T7 terminator
NcoI (70)
AflII (396)
KpnI (1812)
NdeI (531)
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Table 3.1. Conversion of substrates N-Benzyl-pyrrolidine 1 and N-benzyloxycarbonyl-pyrrolidine 
using a whole-cell system.  
 
Whole-cell system 
N-Benzylpyrrolidine 
Conversion  
(30 min) 
N-benzyloxycarbonyl-
pyrrolidine Conversion 
(30 min) 
BL21 pRSFDuet P450pyr pETDuet FR 39.2% 88.3% 
BL21 pACYCDuet P450pyr pETDuet FR 23.8% 87.8% 
BL21 pACYCDuet P450pyr pRSFDuet FR (cells took more than 18 h to grow to saturation)
BL21 pETDuet P450pyr pACYCDuet FR ND 1% 
BL21 pETDuet P450pyr pRSFDuet FR ND 8% 
BL21 pRSFDuet P450pyr pACYCDuet FR ND 1% 
JM109 pCom8 P450pyr FR 0.5% 6.3% 
BL21 pCom8 P450pyr FR 1.9% ND 
 
 
Figure 3.7. SDS-PAGE analysis of control BL21(DE3) pRSFDuet pETDuet (empty vectors) soluble 
(lane 1) and insoluble (lane 2) fractions, as well as BL21 pRSFDuet P450pyr pETDuet FR soluble (lane 
3) and insoluble fractions (lane 4). The P450pyr enzyme was observed as a clear band at 48 kDa.  
 
3.2.3 Iterative Targeted Site Saturation Mutagenesis 
 The mutant library was created using iterative targeted site-saturation 
mutagenesis.37,40,173 The strategy can be described as follows: i) identify all 
residues which are in the vicinity of the heme-docked substrate, ii) perform 
individual site saturation mutagenesis of all or a subset of these selected residues, 
iii) screen each library in 96-well plates, iv) select mutants with improved 
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P450pyr
73 
 
enantioselectivity over wild type (WT), v) perform another round of individual site 
saturation mutagenesis at the remaining unmutated selected residues, and vi) 
repeat steps iii-v until no further improvement can be achieved.  
 Based on the P450pyr homology model, 17 residues were identified within 
5Å of the heme-docked substrate (Fig 3.8a) and were subjected to individual site 
saturation mutagenesis. C366 and G256 were not subjected to randomization 
because they are highly conserved residues involved in the heme coordination and 
catalytic activity of the P450pyr, respectively. For each site, 32 distinct variant 
possibilities exist (32 possible codon substitutions). Hence, the screening of 180 
transformants per site should be more than enough to provide comprehensive 
coverage of all created variants. This protein engineering approach involves 
screening very manageable size of mutant libraries which target the residues 
within the substrate binding pocket.  
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 Our high-throughput screening protocol can be described as following: Firstly, 
the mutant libraries were inoculated and expressed in TB medium in 96-deep well 
plates, in the presence of δ-aminolevulinic acid (δ-ALA) to increase the expression 
level of P450pyr. The biohydroxylation assay to convert 1 to (R)- and (S)-2 was 
performed with resting cells in 96-deep well plates with shaking at 1100 rpm to 
facilitate better mixing and mass transfer. When the biohydroxylation reaction was 
carried out at low shaking speed of 250 to 500 rpm, negligible substrate conversion 
was observed. After the biohydroxylation with whole-cells, the deep well plates were 
centrifuged and aliquots (80 µL) of the supernatant containing the unreacted 1 and its 
racemic product 2 were pipetted into two separate 96-well microtiter plates. In each 
plate, purified BRD or RDR and its corresponding cofactor were added. By utilizing 
the nitro blue tetrazolium (NBT) - phenazine methosulfate (PMS) colorimetric 
assay122, the production of NAD(P)H was monitored by observing the formation of 
partially soluble purple formazan at OD580 which corresponded to the activity of the 
dehydrogenases that in turn is correlated to the concentration of each enantiomer in 
the racemic product (Figure 3.9). Hence, the estimated ee of each mutant could be 
compared against the WT P450pyr. Mutants that showed a greater ee than that of the 
WT were selected and subjected to a larger-scale biohydroxylation assay in shaking 
flasks to verify the enantioselectivity of the mutants by chiral HPLC analysis. 
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Figure 3.9. Example of 96-well microtiter plate screening using the BRD and RDR enzymes coupled 
with the NBT-PMS assay. The formation of purple formazan which correlates to the concentration of 
(S)- and (R)-2 is apparent even to the naked eye and its intensity can be measured using the microplate 
reader. 
 In the first round of saturation mutagenesis, using the WT P450pyr as a 
template, we screened 180 mutants per site, which translates into a total of 3060 
mutants (17 sites) screened. Two interesting mutants with preference for (S)- and 
(R)-2 were identified (Table 3.2). The (S)-selective mutant 11BB12 (F403L) 
displayed an ee of 65% which was a 1.5 times improvement over that of the WT 
P450pyr. Mutant 1AF4 (N100S), on the other hand, displayed a complete reversal 
of enantioselectivity with an ee of 42% with a preference for (R)-2. In fact, it was 
identified twice in the screening of the same 3060-mutant library. It was intriguing 
that only one mutational change at position 100 (replacing asparagine with serine) 
could induce a total inversion of the P450pyr enantioselectivity. 
 Encouraged by the success in the first round, F403L was used as a template 
for a second round of saturation mutagenesis on the remaining 16 residue sites. 
BRD assay to screen 
for (S)-2 
RDR assay to screen 
for (R)-2 
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Unfortunately, we failed to discover any (S)-selective mutants with significantly 
higher ee than the parent 11BB12. Hence, we decided to identify more (R)-
selective mutants instead. Using N100S as a template, a third round of saturation 
mutagenesis was conducted on the remaining 16 residue sites. In this round, we 
discovered four mutants with improved (R)-enantioselectivity ranging from ee of 
60% to 83%. The best mutant, 1AF4A, was sequenced and it was found that the 
mutational change at position 186 (isoleucine substitution of threonine) was 
responsible for the further increase in the (R)-enantioselectivity of the mutant 
P450pyr. 
 
Table 3.2. Hydroxylation of N-benzyl pyrrolidine 1 by engineered cytochrome P450pyr variants. 
 
Description Mutant Amino Acid 
Changes 
Conversion (%)a ee (%)b 
WT P450pyr NA NA 55 43 (S) 
Round 1  1AF4 N100S 33 42 (R) 11BB12 F403L 47 65 (S) 
Round 2  No significantly improved mutants 
Round 3  
1AF4A N100S, T186I 23 83 (R) 
1AF4B N100S, T259S 16 63 (R) 
1AF4C N100S, L302V 19 71 (R) 
1AF4D N100S, V404K 27 60 (R) 
a Conversion determined based on substrate consumption with whole-cell assay (10 g cell dry weight 
(cdw) per liter) using starting substrate concentration  of 5 mM. Biohydroxylation time was 4 h. 
b Determined by chiral HPLC analysis using the Chiralcel OB-H (250 mm x 4.6mm) column. All 
verification experiments were carried out in shaking flasks in triplicates. 
 
 The conversion of 1 by the P450pyr mutants is comparatively lower than 
that of the WT P450pyr (Table 3.2). The conversion of the best mutant 1AF4A 
was more than 50% lower than the WT P450pyr.  The introduction of the mutation 
in the active pocket of the P450pyr has probably introduced a destabilizing effect 
in the enzyme and thus negatively affecting its activity, although the 
enantioselectivity of the enzyme has been significantly improved. For future work, 
we could perhaps take a step back and apply error-prone PCR (epPCR) to the full-
length gene encoding the 1AF4A mutant to improve its activity to a level equal to 
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or higher than the WT P450pyr. 
3.2.5 Combination of Beneficial Mutations by Site Directed Mutagenesis 
 To evaluate the effects of combined mutations, variants with triple mutations 
by combining all the mutations found in Round 3 (Table 3.2) were constructed by site 
directed mutagenesis. Unfortunately, the introduction of these mutations rendered the 
P450pyr enzyme reduced its activity significantly (Table 3.3). Although the ee was 
still reasonably high, ranging from 66 to 81%, there was no improvement over our 
best mutant 1AF4A. Also, the low hydroxylation activity renders the mutants not 
feasible for practical applications. 
Table 3.3. Effect of combination of mutations on substrate conversion and ee 
Mutation sites Conversion (%) ee (%)
N100S T186I V404K 7 66 (R)  
N100S T186I T259S 6 81 (R) 
N100S T259S L302V 6 81 (R) 
N100S T259S V404K 5 78 (R) 
N100S L302V V404K <1 ND 
N100S T186I L302V <1 ND 
 a Conversion determined based on substrate consumption with whole-cell assay (10 g cdw per liter) 
using starting substrate concentration of 5 mM. Biohydroxylation time was 4 h. 
b Determined by chiral HPLC analysis using the Chiralcel OB-H (250 mm x 4.6mm) column. ND: Not 
determined 
 
3.3 Discussion 
3.3.1 Evolutionary Strategy 
 In this chapter, we described the application of a general protein engineering 
approach that we have applied to reengineer the enantioselectivity of the P450pyr 
monooxygenase. We hypothesized that changes in enantioselectivity of the enzyme 
are heavily influenced by the interactions between the substrate and the residues in the 
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active binding pocket. By combining stepwise targeted site saturation mutagenesis of 
the active site protein residues which are within 5Å of the heme-docked substrate, we 
have been able to modify the P450pyr enantioselectivity for substrate 1. Mutants with 
improved (R)- and (S)- selectivity over the WT has been verified and identified.  
 The stepwise individual site saturation mutagenesis strategy has the following 
advantages: (i) Universality: The current library creation strategy can be readily 
generalized to engineer the enantioselectivity of other proteins. Only the homology 
model of the protein is required. (ii) Screenability: There are only 19 possible amino 
acid substitutions or 32 possible codon substitutions per site for the saturation 
mutagenesis libraries. Thus, screening two 96-well plates should be sufficient to 
represent all possible library variants. The library size makes it easier to screen and 
less labor intensive. (iii) Efficiency: Due to the small library size of protein mutants, 
all randomized mutants can be subjected to simultaneous screening for the (R)- and 
(S)-mutants in a faster yet comprehensive manner. These focused libraries are also of 
higher quality, provided the sites to be randomized have been chosen correctly. It 
minimizes the undesired formation of inferior or inactive enzyme mutants and thus 
reduces the overall screening effort, which can be substantial in the case of 
enantioselectivity.132 (iv) Accessibility to amino acid substitutions: Stepwise site 
saturation mutagenesis approach allows every site in the active site pocket to be 
randomized to all 20 possible amino acids, ensuring that important amino acid 
substitutions at critical binding positions are not overlooked.  
 We should also note that the mutants which were identified using the stepwise 
saturation mutagenesis need not represent the only variants with enhanced 
enantioselectivity. The initial template for each round of saturation mutagenesis 
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would influence the next round of mutagenesis and screening. If another mutant were 
chosen as the starting point for the subsequent round of screening, the resultant final 
variant might be a different one. 
3.3.2 Structural Analysis of Mutations 
 The roles played by individual mutations towards altering the 
enantioselectivity of the P450pyr were not clear. The inversion of enantioselectivity 
can arise by the insertion of the O-atom either from the opposite direction into the C-
H bond at the original 3-position or from the same direction into the C-H bond at the 
adjacent position due to the special C(2v) symmetry nature of the pyrrolidine 
substrate. From the homology model, a large cavity allowing substrate access to the 
heme site was observed, with hydrophobic residues lining the entrance to the cavity. 
An interesting observation was that the mutation sites 100, 403, and 186 were located 
near the entrance of the cavity, suggesting that a benzyl ring-protein interaction 
furthest from the heme may induce enantioselectivity towards 1 (See Figure 3.8b). 
The single amino acid substitution of the Asn100 residue by Ser that caused a 
complete inversion of the P450pyr enantioselectivity is of great interest. We reasoned 
that changing the bigger hydrophilic Asn residue to the smaller neutral Ser residue 
would increase the active-site volume and alter the conformation of the helix 
containing the N100S upon substrate binding, which may be responsible for the 
reversal of enantioselectivity. When the neutral Thr residue was also mutated to a 
hydrophobic Ile, the cooperative effect of the two mutations increased the 
enantioselectivity towards the (R)-enantiomer by almost 2 fold.   Interestingly, in both 
cases (N100S and T186I), the residue was replaced by a more hydrophobic residue. 
The Phe403 in the WT P450pyr is located in the middle of the cavity to the active site 
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pocket, thus providing a hydrophobic barrier for the hydrophilic directing groups in 
incoming substrates. In the case of the (S)-enantioselective mutant, 11BB12, the 
aromatic hydrophobic side chain of Phe was replaced by the aliphatic side chain of 
Leu, thus slightly reducing the hydrophobicity which may have directly or indirectly 
increased the mutant’s enantioselectivity towards the (S)-enantiomer due to 
conformational changes at entrance to the enzyme's active site. 
3.4 Conclusions and Outlook 
 In summary, we have inverted the enantioselectivity of the P450pyr towards 
the biohydroxylation of prochiral substrate 1 by iterative targeted site-saturation 
mutagenesis coupled with a high-throughput two-enzyme-based colorimetric assay. 
Interestingly, one mutation at position 100 was all it took to completely invert the 
enantioselectivity of the P450pyr. The best mutant 1AF4A has an ee of 83% (R) 
compared to the wild type’s ee of 43% (S). This inversion was achieved in only two 
rounds of saturation mutagenesis with two mutation sites. In addition, we have also 
discovered the (S)-enantioselective mutant 11BB12 that has an ee of 65% (S).  This 
protein engineering approach involves screening very manageable size of mutant 
libraries which targets the residues within the substrate binding pocket. We have also 
demonstrated the first example in improving the biohydroxylation enantioselectivity 
of a class I P450 monooxygenase via a directed evolution approach combined with an 
ee high-throughput screening assay.  
 Perhaps it would also be beneficial if we took a step back to first improve the 
P450pyr stability before proceeding with further rounds of mutagenesis to improve 
the ee. Extra stability could perhaps confer more evolvability as the stabilized P450 
parent could tolerate the highly destabilizing mutations.174 
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3.5 Materials and Methods 
Materials 
 Escherichia coli BL21(DE3) and the expression plasmids were purchased 
from Novagen (Madison, WI). PCR grade dNTPs were obtained from Roche Applied 
Sciences (Indianapolis, IN). Restriction enzymes, Phusion High-Fidelity DNA 
polymerase, T4 DNA ligase, and their corresponding buffers were purchased from 
New England Biolabs (NEB) (Beverly, MA). D-Glucose was purchased from 
ThermoFisher (Pittsburgh, PA). Ampicillin, kanamycin, isopropyl β-D-
thiogalactopyranoside (IPTG), nitro blue tetrazolium (NBT), phenazine methosulfate 
(PMS), NAD+, and NADP+ were purchased from Sigma (St. Louis, MO). Other 
required salts and reagents were purchased from either Fisher or Sigma-Aldrich. The 
Ni-NTA agarose, QIAprep spin plasmid mini-prep kit, QIAEX II gel purification kit, 
and QIAquick PCR purification kit were purchased from Qiagen (Valencia, CA). 
Various oligonucleotide primers were obtained from Integrated DNA Technologies 
(Coralville, IA). SDS-PAGE gels, buffers and protein size markers were purchased 
from Bio-Rad (Hercules, CA). 
 
Homology Modeling 
 The following structures were downloaded from the Protein Data Bank (PDB) 
database (PDB accession code): CYP119 from Sulfolobus solfactaricus (1F4T) 175 and 
P450st from Sulfolobus tokodaii (1UE8)176. These two structures were aligned using 
Insight II software (Insight II, version 2000; Accelrys Inc., San Diego, CA) based on 
its conserved structural regions to achieve the lowest root-mean-square (RMS) score. 
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The amino acid sequence of P450pyr was manually aligned with the structural 
alignment such that the aligned sequences represented homologous structural regions. 
Using default parameters of the automated MODELER module within Insight II, with 
the alignment as input and using moderate refinement of the structure and loop 
regions, we obtained approximately 30 structural models. By visually inspecting the 
models for obvious flaws, comparing the scores from the Profiles 3-D function, and 
the ProStat inspection of ϕ and ѱ angles, the best model was selected. Docking of 
substrate 1 onto the heme binding site of the best model was carried out using the 
Molecular Operating Environment (MOE; Chemical Computing Group Inc., Montreal, 
Canada). The whole structure was then subjected to energy minimization to relieve 
steric and torsional artifacts from the modeling and docking processes. 
Engineering of a Recombinant E. coli Strain Expressing the Active P450pyr 
 We were interested in engineering a recombinant E. coli strain expressing the 
P450pyr and ferredoxin (Fdx) genes from Sphingomonas sp. HXN200 and the 
ferredoxin reductase (FdR) gene from Mycobacterium sp. HXN1500. Plasmid 
pCom8-PA7F200R1500 131 was used as a PCR template to amplify the coding region 
of cytochrome P450pyr, ferredoxin and ferredoxin reductase. The P450pyr gene was 
amplified using the forward primer P450fwd (5’ TTA ACT ACT CCA TGG AAC 
ATA CAG GAC AAA GCG CGG 3’, the NcoI restriction site is underlined) and 
reverse primer P450rev (5’ TTA ACT ACT GGT ACC CTA CGC GTG GAC GCG 
AAC 3’, the KpnI restriction site is underlined). The Fdx gene was amplified using 
the forward primer Frdxfwd (5’ TTA ACT ACT CCA TGg ca ACA GTG ACC TAT 
GTT GAA ATA AAT GGC AC 3’, the NcoI restriction site is underlined, the second 
codon of the Fdx gene, in small caps, was changed from the original cca to gca) and 
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reverse primer Frdxrev (5’ TTA ACT ACT CTT AAG TCA ATG CTG CGC GAG 
AGG AAG 3’, the AflII restriction site is underlined). The FdR gene was amplified 
using the forward primer R1500fwd (5’ TTA ACT ACT CAT ATG ATC CAC ACC 
GGC GTG AC 3’, the NdeI restriction site is underlined) and the reverse primer 
R1500rev (5’ TTA ACT ACT GGT ACC TTA GAG GGA GGT TGG GGA CG 3’, 
the KpnI restriction site is underlined). PCR amplified genes were digested with their 
respective enzymes. The digested P450pyr fragment was ligated into the pRSFDuet 
vector that was digested with NcoI and KpnI restriction enzymes. The digested Fdx 
fragment was ligated into the multiple cloning site (MCS) 1 of the pETDuet vector 
that was digested with NcoI and AflII. The resulting plasmids from the ligations were 
separately transformed into chemical competent E. coli DH5α cells which were then 
plated on Luria-Bertani (LB) agar plates containing 50 µg/mL kanamycin (for 
pRSFDuet P450pyr) and 100 µg/mL ampicillin (for pETDuet Fdx), respectively. 
Subsequently, the digested FdR fragment was ligated into the MCS 2 of the same 
pETDuet vector, containing the Fdx gene, digested with NdeI and KpnI restriction 
enzymes. The resulting plasmid from the ligation was transformed into chemical 
competent E. coli DH5α cells which were then plated on LB agar plates containing 
100 µg/mL ampicillin. Finally, the purified pRSFDuet P450pyr and pETDuet Fdx 
plasmids were transformed into electrocompetent E. coli BL21(DE3) and plated on 
LB agar plates containing 50 µg/mL kanamycin and 100 µg/mL ampicillin. 
 
Library Generation 
 Megaprimer PCR method was used to generate libraries where single residues 
were randomized to all 20 possible amino acids. In the first round of saturation 
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mutagenesis, pRSFDuet P450pyr wild type plasmid was used as template. Briefly, 
three primers were used to generate an amplified gene library consisting of a 
saturation mutagenized residue: two primers flanking the P450pyr region (PF200fwd, 
5’-TTA ACT ACT CCA TGG AAC ATA CAG GAC AAA GCG CGG-3’, and 
P450rev KpnI, 5’-TTA ACT ACT GGT ACC CTA CGC GTG GAC GCG AAC-3’) 
and a degenerate primer incorporating the residue to be mutated. The degenerate 
primer substituted the codon corresponding to the target residue with the sequence 
NNS and contained 9-10 additional bases on either side (5' and 3'). The NNS 
substitution allowed the incorporation of all 20 amino acids while limiting the codon 
possibilities to only 32. For each gene library with a randomized codon, 2 PCRs were 
performed. Firstly, the megaprimer containing the NNS substitution at the codon of 
interest was amplified. Each PCR contained (50 mL of final volume): 1X  Phusion HF 
buffer, 0.2 mM of each dNTP (Roche), 0.5 µM of appropriate degenerate primer, 0.5 
µM of appropriate flanking primer (PF200fwd or P450rev KpnI), and 50 ng of 
template plasmid. PCRs were carried out on a MJ Research (Watertown, MA) PTC-
200 thermocycler with cycle conditions of 98 °C 30 s, (98 °C 10 s, 58 °C 30 s, and 
72 °C 15 s) × 25 cycles and 72 °C 10 min. The megaprimer product was purified and 
eluted into 50 µL EB buffer using the QIAquick PCR purification kit. 10 μL of the 
megaprimer was then combined into a 100 µL PCR reaction which shares the same 
conditions to the first PCR step described above, except that the primers used were 
replaced with the megaprimer and its corresponding flanking primer, and a different 
program was used: 98 °C 30 s, (98 °C 10 s, 58 °C 30 s, and 72 °C 45 s) × 30 cycles 
and 72 °C 10 min. PCR product from this reaction was purified from a 1% agarose gel 
by using the QIAEX II gel purification kit. The insert was digested with NcoI and 
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KpnI and ligated into the pRSFDuet vector. This library was electroporated into E. 
coli BL21(DE3) competent cells containing the pETDuet Fdx FdR vector. 
 
Library Screening 
 For identification of enantioselective P450pyr variants, a 96-well plate two-
enzyme based colorimetric assay was developed based on a colorimetric nitro blue 
tetrazolium (NBT) - phenazine methosulfate (PMS) 122. Library colonies were picked 
with sterile toothpicks and used to inoculate 500 µL of TB medium containing 50 
µg/mL kanamycin and 100 µg/mL ampicillin in 96-deep well (2 mL) plates. The 
plates were shaken at 500 rpm, 37 °C for 6 h, and protein expression was induced by 
adding 500 µL of TB medium containing 0.5 mM IPTG and 0.5 mM δ-ALA, 
followed by shaking at 500 rpm, 30 °C for 14 h. The plates were centrifuged at 4000 
rpm for 10 min at 4 °C, and the cells were resuspended in 300 µL of 50 mM 
potassium phosphate buffer pH 7.0 containing 2 % (w/v) D-glucose and 10 mM of 1. 
The plates were then shaken at 1100 rpm, 30 °C for 5 h and were later centrifuged at 
4000 rpm for 10 min at 4 °C. An aliquot (80 µL) of the supernatant was transferred to 
two fresh plates, one containing ~5 µg BRD enzyme while the other plate contained 
~5 µg of the RDR enzyme. The NBT assay solution (final concentration 2 mg/mL 
NBT, 0.1 mg/mL PMS, 0.5 mM NAD(P)H) was added to each plate to initiate the 
reaction. The plates were incubated at room temperature in darkness for 2.5 h and the 
absorbance at 580 nm was measured in a SpectraMax 340PC microplate reader 
(Molecular Devices, Sunnyvale, CA). Enantioselective mutants were identified by 
comparing the ratio of the absorbance on both plates against that of the parent enzyme.  
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Whole-cell Assay in Shaking Flasks  
 To confirm the positive mutants, they were streaked on LB plates containing 
50 µg/mL kanamycin and 100 µg/mL ampicillin, and single colonies were picked into 
5 mL of liquid LB medium containing the antibiotics. After shaking at 37 °C 
overnight, 1 mL of the culture were inoculated into 10 mL of liquid TB medium 
containing the antibiotics, 0.5 mM IPTG and 0.5 mM δ-ALA. The culture was shaken 
at 250 rpm, 30 °C for 6 h and then centrifuged at 4000 rpm for 5 min at 4 °C. The 
cells were resuspended (to 10 g cell dry weight per liter) in 50 mM potassium 
phosphate buffer pH 7.0 containing 2 % (w/v) D-glucose and 10 mM of 1, and further 
shaken at 250 rpm, 30 °C for 4 h. After centrifuging at 4000 rpm, 80 µL aliquot of the 
supernatant was taken to be analyzed by using the Hypersil BDS-C18 (5 µm) column 
(15 mm × 4 mm) on the reverse-phase HPLC 130. The chiral product in the remaining 
supernatant was extracted using ethyl acetate in a standard work up procedure and the 
chirality was analyzed by using the Chiralcel OB-H (250 mm x 4.6mm) column 126. 
The ee’s of the positive mutants were verified in triplicates. 
 
Site Directed Mutagenesis  
 Overlap extension PCR method was used introduce mutations at desired 
locations. As an example, to introduce 3 different mutations, the mutant already 
containing 1 of the mutation was used as a template so that we only need to introduce 
another 2 more mutations. As illustrated in Figure 3.10, six primers were used: two 
primers (aF and dR) flanking the template and 2 pairs of complementary degenerate 
primers (bF and bR, cF and cR) incorporating the residue to be mutated. The 
degenerate primer substituted the codon corresponding to the target residue with the 
mutation desired and contained 9-10 additional bases on either side (5' and 3'). For 
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each triple mutant, only 2 PCR rounds need to be performed. In PCR Round 1, three 
fragments: AB, BC and CD, containing the desired mutation were amplified using the 
forward and reverse primer pairs aF and bR, bF and cR, as well as cF and dR, 
respectively. Each PCR contained (50 mL of final volume): 1×  Phusion HF buffer, 
0.2 mM of each dNTP (Roche), 0.5 µM of the primer pairs, and 50 ng of template 
plasmid. PCRs were carried out on a MJ Research (Watertown, MA) PTC-200 
thermocycler with cycle conditions of 98 °C 30 s, (98 °C 10 s, 58 °C 30 s, and 72 °C 
15 s) × 25 cycles and 72°C 10 min. The PCR amplified fragments from this reaction 
was purified from a 1% agarose gel and eluted into 30 µL EB buffer using the QIAEX 
II gel purification kit. In PCR Round 2, ~50ng of each fragment and the template 
flanking primers, aF and dR, were then combined into a 100 µL PCR reaction which 
shares the same conditions to the first PCR step described above, except the template 
was replaced with the 3 fragments and a different program was used: 98 °C 30 s, 
(98 °C 10 s, 58 °C 30 s, and 72 °C 45 s) × 30 cycles and 72 °C 10 min. The PCR 
product was PCR purified using the QIAquick PCR purification kit, digested with 
NcoI and KpnI and ligated into the pRSFDuet vector. This triple mutant was then 
electroporated into E. coli BL21(DE3) competent cells containing the pETDuet Fdx 
FdR vector and subsequently subjected to a whole-cell assay to determine its substrate 
conversion % and ee. 
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Chapter 4 : Development of a Simple, Efficient and General Method 
for Cofactor Recycling in a Bio-Oxidation 
4.1 Introduction 
 The majority of the enzymes that are now being developed or are currently 
utilized in industry are mostly hydrolytic in nature.65-67  These enzymes may be 
applied in the form of whole-cells or as isolated enzymes in a soluble or immobilized 
state. Classes of enzymes such as hydrolases, isomerases or lyases are cofactor-
independent, or have a cofactor like a metal ion or a coenzyme that is firmLy bound. 
In contrast,  enzymes such as oxidoreductases, transferases and ligases are cofactor-
dependent and have been found to perform more complex chemistry that are 
synthetically useful.67-72 For example, NAD(P)H-dependent cytochrome P450s 
catalyze hydroxylation, N-, O-, S-dealkylation, sulphoxidation, epoxidation, 
deamination, desulphuration, dehalogenation, peroxidation and N-oxide reduction12, 
NAD-dependent oxidoreductases catalyze the asymmetric reduction of carbonyl 
groups to alcohols and amines72,73 and coenzyme A-dependent (CoA) synthetases 
catalyze asymmetric carbon-carbon bond formation.74-77  However, as these enzymes 
use expensive cofactors, they have not been as widely applied in industrial settings 
compared to cofactor-independent enzymes. 
 In a cell, the pyridine nucleotide cofactors NAD+/NADH and NADP+/NADPH 
are essential components as they function as electron carriers in reduction and 
oxidation reactions. Whole-cell biocatalysis provide a continuous source of enzymes 
and cofactors, and is thus generally preferred over purified enzymes in industrial 
settings, especially for cofactor-dependent biotransformations. Although it is known 
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that whole-cells have some reserves of cofactors, cofactor depletion is often a limiting 
factor in whole-cell-catalyzed reactions. Thus, in order for a cofactor-dependent 
reaction to be practical, an efficient recycling of the cofactor is necessary. 
 Strategies for nicotinamide cofactor regeneration can be classified into four 
general categories: biological, enzymatical, electrochemical, chemical and 
photochemical.79-87 The enzymatical strategy can be further divided into the coupled-
substrate81,177-179 and the coupled-enzyme approaches.123,180-187 In the former, only one 
enzyme is used to catalyze both the main and the regeneration reactions. This method 
is suitable for systems that use enzymes in organic media because the organic solvent 
is used as a substrate. The drawback of this method is that the choice of the co-
substrate is limited by the enzyme’s substrate specificity. The coupled-enzyme 
approach, on the other hand, is a more general and preferred approach. It utilizes the 
first enzyme for the desired biotransformation and a second enzyme and a second 
substrate for cofactor regeneration. Formate dehydrogenase180,182 and glucose 
dehydrogenase (GDH)186,187 are commonly used as the second enzyme for the 
regeneration of NAD(P)H. The coupled-enzyme concept has been successfully 
demonstrated using two isolated-enzymes180,182,185-187, whole-cells co-expressing the 
both enzymes181,183,184 and coupled permeabilized cells system118. Schrader and 
colleagues have also developed a recombinant E. coli expressing the P450BM3 with an 
additional heterologous NADPH regeneration system comprising glucose facilitator 
and dehydrogenase. However, the product yield (based on cell dry weight) for this 
cofactor regeneration system did not show any improvement over the recombinant E. 
coli expressing the P450BM3 alone.160 
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 As described in Chapter 3, we have constructed a highly active Escherichia 
coli recombinant expressing the P450pyr system. Here, we are interested to increase 
the productivity of this recombinant strain by introducing a cofactor regeneration 
system in vivo. In this chapter, two cofactor regeneration systems utilizing either the 
glucose dehydrogenase118 (GDH) from Bacillus substilis BGSC 1A1 or the 
engineered phosphite dehydrogenase 12x33,123 (PTDH 12x) from Pseudomonas 
stutzeri were explored.  
4.2 Results and Discussion 
4.2.1 Construction of Recombinant E. coli Strains 
 We have constructed various E. coli strains expressing the four genes, 
including the P450pyr and ferredoxin (Fdx) genes from Sphingomonas sp. HXN200, 
the ferredoxin reductase (FdR) gene from Mycobacterium sp. HXN1500, and the 
cofactor regeneration component, GDH or PTDH 12x. These genes were inserted into 
various expression vectors in different combinations (Table 4.1). For example, 
P450pyr and GDH were inserted into the pRSFDuet, pCDFDuet, and pACYCDuet to 
construct pRSFDuet PG, pCDFDuet PG, and pACYCDuet PG, respectively. Similarly, 
Fdx and FdR were inserted into pETDuet to construct pETDuet FR. Similarly, Fdx 
and FdR were inserted into pETDuet to construct pETDuet FR. The constructed 
plasmids were then transformed into E. coli BL21(DE3) to obtain different strains 
with 2- and 3-plasmid systems (Figure 4.1). 
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Table 4.1. Various E. coli BL21(DE3) strains with 2- and 3-plasmid systems constructed in this study.  
Strain Host Plasmids
Rp450 BL21(DE3) pRSFDuet P450, pETDuet FR 
Cp450 BL21(DE3) pCDFDuet P450, pETDuet FR 
Ap450 BL21(DE3) pACYCDuet P450, pETDuet FR 
A1 BL21(DE3) pRSFDuet P450, pETDuet FR, pACYCDuet GDH 
A2 BL21(DE3) pRSFDuet P450, pETDuet FR, pACYCDuet 12x 
A3 BL21(DE3) pRSFDuet P450, pETDuet FR, pCDFDuet GDH 
A4 BL21(DE3) pRSFDuet P450, pETDuet FR, pCDFDuet 12x 
Rgdh BL21(DE3) pRSFDuet PG, pETDuet FR 
R12x BL21(DE3) pRSFDuet P12x, pETDuet FR 
Cgdh BL21(DE3) pCDFDuet PG, pETDuet FR 
C12x BL21(DE3) pCDFDuet P12x, pETDuet FR 
Agdh BL21(DE3) pACYCDuet PG, pETDuet FR 
A12x BL21(DE3) pACYCDuet P12x, pETDuet FR 
FR: Fdx and FdR cloned into the same plasmid. PG: P450 and GDH cloned into the same plasmid. 
P12x: P450pyr and PTDH 12x cloned into the same plasmid. 
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Figure 4.1. Selected examples of plasmid maps of pRSFDuet P450, pETDuet FR, pRSFDuet PG, 
pRSFDuet P12x, pACYCDuet GDH and pACYCDuet 12x. The green sections are the genes that were 
cloned into the plasmid.  
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4.2.2 Cell Culture and Protein Expression 
 As a quick initial test of activity, the E. coli BL21(DE3) strains were cultured 
and induced with 0.5 mM IPTG for protein expression. After 5 h of shaking at 250 
rpm and 30 ºC, the cells were harvested and subjected to whole-cell assays as 
described in the Materials and Methods section. The strains with three plasmids grew 
the fastest but did not show any activity. When they were harvested after 5 h of 
induction, these cells were of the same color as the non-induced controls, rather than 
the dark pinkish color which would have been expected if P450pyr was expressed in 
the cell. When the cell-free extracts of these 3-plasmid strains were analyzed by SDS-
PAGE, the P450pyr band was missing indicating that the P450pyr was hardly 
expressed at all. Hence, we switched our focus to the two-plasmid systems instead. 
The cell-free extracts of selected strains were analyzed by SDS-PAGE (Figure 4.2). 
 
Figure 4.2. SDS-PAGE of non-induced R12x control (lane 1), Rgdh (lane 2), R12x (lane 3) and A2 
(lane 4) 
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4.2.3 Biohydroxylation of N-Benzyl-pyrrolidine 1 with Recombinant E. coli 
Strains Expressing the P450pyr and Cofactor Regeneration System 
 The potential for increasing the productivity of N-benzyl-3-
hydroxypyrrolidine 2 from the biohydroxylation of N-benzyl-pyrrolidine 1 was 
explored by introducing a cofactor regeneration system by utilizing either the GDH 
from Bacillus substilis BGSC 1A1 or the engineered PTDH 12x from Pseudomonas 
stutzeri (Scheme 4.1). The biohydroxylation of 1 to 2 is of great interest as these 
enantiomers are important pharmaceutical intermediates in the synthesis of a k-
receptor agonist, an antibacterial agent, carbapenem antibiotics, and a 5-HT1Da 
receptor agonist.126 In the regeneration of NADH from NAD+, the GDH converts 
glucose to gluconolactone whereas the PTDH 12x converts phosphite (HPO32-) to 
phosphate (HPO42-). For the GDH system, we investigated the biohydroxylation of 
three different strains, Rgdh, Cgdh, and Agdh (Table 4.1), in which the P450 and 
GDH genes were both expressed together on one of the following plasmids: 
pRSFDuet, pCDFDuet, or pACYCDuet.  Similarly, for the PTDH 12x system, we 
used three different strains, R12x, C12x, and A12x. The activities and product 
concentration-time curves of these strains were compared to those of the parental 
strains, Rp450, Cp450, and Ap450. The whole-cell assay was carried out as described 
in Materials and Methods with samples taken at different time intervals. 
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Scheme 4.1. Biohydroxylation of substrate N-benzyl pyrrolidine 1 to its corresponding (R)- and (S)-N-
benzyl-3-hydroxypyrrolidines 2 with NADH regeneration using (a) phosphite dehydrogenase (PTDH 
12x)  and (b) glucose dehydrogenase (GDH). 
  
 For the GDH cofactor regeneration system (Figure 4.3), the best strain was the 
Rgdh with a specific activity of 8.89 U/g cdw that was 1.6x higher than its parent 
strain Rp450 (without GDH gene) that has a specific activity of 5.48 U/g cdw (Table 
4.2). The Rgdh strain produced up to 1.89 mM and 2.03 mM of 2 at 5 h and 26 h, 
respectively, compared to its parent strain Rp450 which produced only 1.44 mM and 
1.75 mM of 2 at 5 h and 26 h, respectively. The Cgdh strain showed no improvement 
in its specific activity (or productivity) when compared to its parent Cp450 strain. On 
the other hand, the Agdh strain demonstrated a slight 1.2x increase in specific activity 
over its parent Ap450 strain, with 7.71 U/g cdw compared to 6.27 U/g cdw. At 26 h, it 
produced up to 2.34 mM of 2 compared to its parent Ap450 strain which produced 
1.98 mM of 2. Hence, the introduction of a GDH cofactor regeneration system into 
the P450pyr system increased its activity (and productivity), with the Rgdh strain 
showing the highest improvement over its parental strain. 
b)a) 
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Table 4.2. Specific activity for the biohydroxylation of 1 by various strains with the GDH and PTDH 
12x systems. Activity was determined over the first 1h. 
GDH system PTDH 12x system 
Strain Specific Activity (U/g cdw) Strain Specific Activity U/g cdw 
Rp450 5.48 Rp450 3.48 
Rgdh 8.89 R12x 8.67 
Cp450 5.79 Cp450 4.28 
Cgdh 5.02 C12x 3.49 
Ap450 6.27 Ap450 5.22 
Agdh 7.71 A12x 6.29 
 
 For the PTDH 12x cofactor regeneration system (Figure 4.4), the best strain 
was the R12x with a specific activity of 8.67 U/g cdw that was 2.5x higher than its 
parent strain Rp450 (without PTDH 12x gene) which has a specific activity of 3.48 
U/g cdw. The R12x strain produced up to 1.96 mM and 2.28 mM of 2 at 5 h and 26 h, 
respectively, while its parent strain Rp450 produced only 1.00 mM and 1.70 mM of 2 
at 5 h and 26 h, respectively. The C12x strain showed no improvement in its specific 
activity (or productivity) when compared to its parent Cp450 strain. On the other hand, 
the A12x strain demonstrated a slight 1.2x increase in specific activity over its parent 
Ap450 strain, with 6.29 U/g cdw compared to 5.22 U/g cdw. At 26h, it produced up to 
2.20 mM of 2 compared to its parent Ap450 strain which produced 1.93 mM of 2. 
Hence, the introduction of a PTDH 12x cofactor regeneration system into the P450pyr 
system increased its activity (and productivity), with the R12x strain showing the 
highest improvement over its parental strain.  
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Figure 4.3. GDH cofactor regeneration system. Plot of product concentration (mM) versus time (h) for 
various strains. The whole-cell assay (10 mL total volume) was carried out in 125 mL shaking flasks 
with cell density of 1.5 g cdw/L, 8 % (w/v) glucose and 5 mM substrate 1 in 50 mM potassium 
phosphate buffer. 
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Figure 4.4. PTDH 12x cofactor regeneration system. Plot of product concentration (mM) versus time 
(h) for various strains. The whole-cell assay (10 mL total volume) was carried out in 125 mL shaking 
flasks with cell density of 1.5 g cdw/L, 2 % (w/v) glucose, 200 mM sodium phosphite and 5 mM 
substrate 1 in 50 mM potassium phosphate buffer. 
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4.2.4 Biohydroxylation of N-Benzyl-pyrrolidin-2-one 3 with Recombinant E. 
coli Strains Expressing the P450pyr and Cofactor Regeneration System 
 The potential for increasing the productivity of N-benzyl-4-hydroxypyrrolidin-
2-one 4 from the biohydroxylation of N-benzyl-pyrrolidin-2-one 3 was explored by 
introducing a GDH cofactor regeneration system by utilizing either the GDH from 
Bacillus substilis BGSC 1A1 or the engineered PTDH 12x from Pseudomonas 
stutzeri (Scheme 4.2). This hydroxylation reaction is of great interest as it produces 4, 
a very useful pharmaceutical intermediate, with an ee of > 99.9% (S). Similar to the 
previous section with substrate 1, we investigated three different strains, Rgdh, Cgdh, 
and Agdh (Table 4.1) for the GDH system, and another three different strains, R12x, 
C12x, and A12x for the 12x system. The whole-cell assay was carried out as 
described in Materials and Methods with samples taken at different time intervals. 
 For the GDH cofactor regeneration system (Figure 4.5), the best strain was the 
Agdh with a specific activity of 5.02 U/g cdw that was 1.2x higher than its parent 
strain Ap450 (without GDH gene) which has a specific activity of 4.09 U/g cdw 
(Table 4.3). The Agdh strain produced up to 1.73 mM of 4 at 23 h compared to its 
parent strain Ap450 which produced only 1.32 mM of 4 at 23 h. The Cgdh strain 
showed no improvement in its specific activity (or productivity) when compared to its 
parent Cp450 strain. On the other hand, the Rgdh strain demonstrated a slight 1.1x 
increase in specific activity over its parent Rp450 strain, with 4.39 U/g cdw compared 
to 4.17 U/g cdw. At 23 h, it produced up to 1.43 mM of 4 compared to its parent 
Rp450 strain which produced 1.14 mM of 4. Hence, the introduction of a GDH 
cofactor regeneration system into the P450pyr system increased its activity (and 
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productivity), with the Agdh strain showing the highest improvement over its parental 
strain. 
 
 
Scheme 4.2. Biohydroxylation of substrate N-benzyl-pyrrolidin-2-one 3 to its corresponding (S)- and 
(R)-N-benzyl-4-hydroxypyrrolidin-2-ones 4 with NADH regeneration using (a) phosphite 
dehydrogenase (PTDH 12x)  and (b) glucose dehydrogenase (GDH).  
  
Table 4.3. Specific activity of various strains with the GDH and PTDH 12x systems. Activity was 
determined over the first 30 min. 
GDH system PTDH 12x system 
Strain Specific Activity (U/g cdw) Strain Specific Activity (U/g cdw) 
Rp450 4.17 Rp450 4.56 
Rgdh 4.39 R12x 4.81 
Cp450 4.64 Cp450 4.44 
Cgdh 3.98 C12x 4.54 
Ap450 4.09 Ap450 3.23 
Agdh 5.02 A12x 5.91 
 
 For the PTDH 12x cofactor regeneration system (Figure 4.6), the best strain 
was the A12x with a specific activity of 5.91 U/g cdw that was 1.8x higher than its 
parent strain Ap450 (without PTDH 12x gene) which has a specific activity of 3.23 
U/g cdw. The A12x strain produced up to 1.65 mM of 4 at 23 h compared to its parent 
strain Ap450 which produced only 1.36 mM of 4 at 23 h. The C12x strain showed no 
b)a) 
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improvement in its specific activity (or productivity) when compared to its parent 
Cp450 strain. On the other hand, the R12x strain demonstrated a very slight 1.1x 
increase in specific activity over its parent Ap450 strain, with 4.81 U/g cdw compared 
to 4.56 U/g cdw. Hence, the introduction of a PTDH 12x cofactor regeneration system 
into the P450pyr system increased its activity (and productivity), with the A12x strain 
showing the highest improvement over its parental strain. 
 We are interested to know the effect of increasing substrate 3 concentration on 
the whole-cell productivity curve for strains Ap450, Agdh and A12x (Figure 4.7). 
When the initial concentration of substrate 3 was increased to 10, 15 and 20 mM, the 
overall productivity fell by about 33% with each increase of 5 mM. The A12x strain 
has the highest productivity, followed by the Agdh. Nevertheless, the differences 
between all three strains became less obvious as initial substrate concentration was 
increased. This indicates that the substrate 3 has an inhibitory effect towards the 
enzyme activity. With a continuous supply of NADH regenerated by the PTDH 12x, 
the biohydroxylation reaction with the A12x strain continued up to the 10.5 h whereas 
the production of 4 with the Ap450 strain started to plateau off at 5 h. For the Agdh 
strain, the productivity is generally lower than that of the A12x strain but higher than 
that of the Ap450 strain. This can perhaps be attributed to the competition between 
our GDH system and the cell’s natural metabolism for the glucose. Nevertheless, at 
initial substrate concentration of 10 mM, the Agdh strain continuously catalyzed the 
biohydroxylation of substrate 3 to product 4 even at the 26th hour. 
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Figure 4.5. GDH cofactor regeneration system. Plot of product concentration (mM) versus time (h) for 
various strains. The whole-cell assay (10 mL total volume) was carried out in 125 mL shaking flasks 
with cell density of 1.5 g cdw/L, 2 % (w/v) glucose and 5 mM substrate 3 in 50 mM potassium 
phosphate buffer. 
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Figure 4.6. PTDH 12x cofactor regeneration system. Plot of product concentration (mM) versus time 
(h) for various strains. The whole-cell assay (10 mL total volume) was carried out in 125 mL shaking 
flasks with cell density of 1.5 g cdw/L, 2 % (w/v) glucose, 200 mM sodium phosphite and 5 mM 
substrate 3 in 50 mM potassium phosphate buffer. 
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Figure 4.7. Comparison of strain productivity (for Ap450, Agdh and A12x) with different starting 
concentration of substrate 3 (10, 15 and 20 mM). Biotransformation was performed with cell density of 
1.5 g cdw/L. 
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Figure 4.8. Plot of product concentration (mM) versus time (h). Biotransformation was performed with 
cell density of 5 g cdw/L, 2 % (w/v) glucose, 200 mM sodium phosphite (for PTDH 12x system) and 
10 mM substrate 3 in 50 mM potassium phosphate buffer. 
 
 When a higher cell density was used in the biotransformation with an initial 
substrate 3 concentration of 10 mM (Figure 4.8), the A12x strain produced up to 4.33 
mM of 4 at 23 h compared to the parent strain Ap450 of just 2.72 mM of 4, a 1.6x 
improvement in productivity. Unexpectedly, the product concentration-time curve for 
the Agdh strain did not show any difference in productivity when compared to the 
parent strain Ap450. This is perhaps related to the competition for glucose by the 
newly introduced GDH system and the cell’s natural GDH system.  
 Although E. coli BL21(DE3) has its own internal cofactor recycling system, 
the incorporation of an additional cofactor recycling system in vivo increased the 
availability of NADH in the system, thus enabling the P450pyr to be utilized more 
efficiently. Also, the product formation period was also prolonged thus increasing the 
productivity of the P450pyr. 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 5 10 15 20 25
Co
nc
 o
f 4
/m
M
Time/h
Ap450
Agdh
A12x
108 
 
 Productivity improvement varied when different expression vectors were used 
due to the different copy number of plasmids in the system, resulting in different 
ratios of protein expressed within the system. One could also expect the expression 
level of the proteins to be different depending on the order it was cloned. 
The addition of 200 mM of sodium phosphate into the PTDH 12x system has 
also been found to affect the specific activity for Rp450, Cp450 and Ap450 (Table 
4.2). This can be attributed to the high salt concentration in the solution, thus affecting 
the ionic strength in the reaction mixture.  
The conversion of glucose to gluconolactone resulted in the lowering of the 
pH of the whole-cell reaction mixture which would inadvertently affect the optimum 
activity of the enzymes. Hence, the pH would have to be checked at every 3-4 h 
interval and readjusted back to pH 7.5. On the other hand, for the PTDH 12x system, 
phosphate accumulation is not a problem as P450pyr and PTDH 12x are not inhibited 
by phosphate, which can also be used as to buffer the assay, and phosphate can be 
easily removed downstream if necessary by ionic filtration or precipitation as a 
calcium salt. 
 
4.3 Conclusion and Outlook 
 The incorporation of a GDH or PTDH 12x cofactor regeneration system 
together with the P450pyr system in a recombinant E. coli has resulted in an increase 
in activity and productivity, i.e. the product formation period was prolonged. Using 
substrate 1, the R12x strain demonstrated 2.5x higher activity than its parent strain 
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Rp450, whereas the Rgdh strain gave a 1.6x higher activity than the parent strain. On 
the other hand, when utilizing substrate 3, the A12x strain demonstrated 1.8x higher 
activity than its parent strain Ap450, whereas the Agdh strain demonstrated only a 
1.2x increase compared to its parent strain. When a cell density of 5 g cdw/L and 10 
mM initial substrate 3 were used, up to 4.33 mM of 4 (ee > 99.9% (S)) was produced 
by A12x at 23 h compared to the parent strain Ap450 with just 2.72 mM of 4. Further 
optimization work would be necessary to increase the productivity level of this system. 
This method could also be applied to other microbial biohydroxylation reactions. 
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4.4 Materials and Methods 
Materials 
 Escherichia coli BL21(DE3) and the expression plasmids were purchased 
from Novagen (Madison, WI). PCR grade dNTPs were obtained from Roche Applied 
Sciences (Indianapolis, IN). Restriction enzymes, Phusion High-Fidelity DNA 
polymerase, T4 DNA ligase and their corresponding buffers were purchased from 
New England Biolabs (NEB) (Beverly, MA). D-glucose was purchased from 
ThermoFisher (Pittsburgh, PA). Ampicillin, kanamycin, isopropyl β-D-
thiogalactopyranoside (IPTG), nitro blue tetrazolium (NBT), phenazine methosulfate 
(PMS), NAD+, and NADP+ were purchased from Sigma (St. Louis, MO). The Ni-
NTA agarose, QIAprep spin plasmid mini-prep kit, QIAEX II gel purification kit, and 
QIAquick PCR purification kit were purchased from Qiagen (Valencia, CA). Various 
oligonucleotide primers were obtained from Integrated DNA Technologies (Coralville, 
IA). SDS-PAGE gels, buffers and protein size markers were purchased from Bio-Rad 
(Hercules, CA). All other required chemical reagents and solvents were purchased 
from Acros Organics (Morris Plains, NJ) and Sigma-Aldrich (St. Louis, MO). 
Strain Construction 
 The P450pyr was cloned into pRSFDuet, and the Fdx and FdR were cloned 
into the pETDuet as described in Chapter 3. To construct the plasmids listed out on 
Table 4.1, the P450pyr and GDH or PTDH 12x genes were amplified by PCR using 
an MJ Research PTC-200 thermal cycler with the following program: 
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PCR program: 
1 = 98 °C for 0:30 
2 = 98 °C for 0:10 
3 = 55-65 °C for 0:45 
4 = 72 °C for 0:30 to 1:00 
5 = Goto 2, 24 times 
6 = 72 °C for 10:00 
7 = 4 °C for ever 
8 = End 
 
 The PCR amplified fragments were then digested with their respective 
enzymes and cloned into separate plasmids (Table 4.4). For plasmids with two genes, 
the P450pyr was ligated into the plasmid first, followed by the second gene, GDH or 
PTDH 12x. The resulting plasmids from the ligations were separately transformed 
into chemical competent E. coli DH5α cells which were then plated on Luria-Bertani 
(LB) agar plates with appropriate antibiotics. Finally, the purified plasmids were 
transformed into electrocompetent E. coli BL21(DE3) cells and plated on LB agar 
plates containing the appropriate antibiotics. 
Table 4.4. Construction of different plasmids. Primers and restriction sites used are shown below. The 
same genes were ligated into different vectors as listed below. 
Gene to be amplified Primers (Restriction sites 
underlined) 
Cloned into … 
P450pyr 
Template: pCom8-
PA7F200R1500131 
PF200fwd NcoI: TTA ACT 
ACT CCA TGG AAC ATA 
CAG GAC AAA GCG CGG 
 
P450 rev AflII: TTA ACT ACT 
CTT AAG CTA CGC GTG 
GAC GCG AAC 
 
MCS I of pRSFDuet, 
pCDFDuet and pACYCDuet 
GDH 
Template: pUC18 GDH 
(Obtained from Prof Li Zhi’s lab 
strain collection) 
 
GDH fwd BglII: TTA ACT 
ACT AGA TCT ATG TAT 
CCG GAT TTA AAA GGA 
AAA GTC GTC  
 
GDH rev XhoI: TTA ACT 
ACT CTC GAG TTA ACC 
GCG GCC TGC C     
 
 
MCS II of pRSFDuet, 
pCDFDuet and pACYCDuet 
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GDH fwd NcoI: TTA ACT 
ACT CCA TGG AT CCG GAT 
TTA AAA GGA AAA GTC 
GTC 
 
GDH rev KpnI: TTA ACT 
ACT GGT ACC TTA ACC 
GCG GCC TGC C 
pACYCDuet 
PTDH 12x 
Template: pET15b 12x 
(Obtained from Prof Zhao’s lab 
strain collection) 
 
12X F BglII: TTA ACT ACT 
AGA TCT ATG CTG CCG 
AAA CTC GTT ATA ACT C 
 
12X R XhoI: TTA ACT ACT 
CTC GAG TTA TCA GTC 
TGC GGC AGG ATT G  
 
MCS II of pRSFDuet, 
pCDFDuet and pACYCDuet 
12X F SacI: TTA ACT ACT 
GAG CTC ATG CTG CCG 
AAA CTC GTT ATA ACT C 
 
12X R KpnI: TTA ACT ACT 
GGT ACC TTA TCA GTC 
TGC GGC AGG ATT G 
pACYCDuet 
 
Cell Culture and Protein Expression  
 The recombinant E. coli strain was streaked on an LB agar plate with 
appropriate antibiotics and incubated overnight at 37 ºC. A single colony from the 
plate was inoculated into 5 mL of LB media with appropriate antibiotics and was 
grown overnight at 37 ºC and 250rpm. Next, 25 mL of TB media with the appropriate 
antibiotics was inoculated with 1% (v/v) of the overnight culture and grown to mid-
log phase (OD600 of ~0.6). The gene expression was induced by adding 0.5 mM IPTG 
and 0.5 mM δ-aminolevulinic acid (δ-ALA), and the cells were continuously shaken 
at 250 rpm at 30 ºC for 5 h. The cells were then harvested by centrifugation and 
resuspended in 50 mM potassium phosphate buffer (pH 7.5) to a cell density of 10 g 
cdw/L. 
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 The cell suspension (10 g cdw/L) was passed twice through a homogenizer at 
20 kpsi. The cell debris was removed by centrifugation at 13,000 rpm at 4 ºC for 20 
min. The supernatant was diluted and subjected to analysis with SDS-PAGE.  
Whole-Cell Assay 
 For GDH-based systems, a whole-cell assay was prepared with 1.5 g cdw/L of 
cell suspension, 2 to 8 % (w/v) glucose, 5 to 20 mM substrate 1 or 3 in 50 mM 
potassium phosphate buffer (pH 7.5) (Total volume 10 mL).   
 For PTDH 12x-based systems, a whole-cell assay was prepared with 1.5 to 5 g 
cdw/L of cell suspension, 0.2 M sodium phosphite, 2 % (w/v) glucose, 5 to 20 mM 
substrate 1 or 3 in 50 mM potassium phosphate buffer (pH 7.5) (Total volume 10 mL).   
 The mixtures were shaken at 30 ºC and 250 rpm. At different time points, 200 
µL samples were taken and centrifuged for 2 min at 13,000 rpm. The supernatant 
from these samples were then subjected to HPLC analysis. 
Analytical Method 
 The concentration of N-benzyl-3-hydroxypyrrolidine 2 was analyzed by 
Shimadzu Prominence HPLC using a Agilent Eclipse Plus C18 (3.5 µm) column (4.6 
x 150 mm), UV detection at 210 nm, flow rate of 1 mL/min; eluent A, acetonitrile, 
and eluent B, 10 mM potassium phosphate buffer (pH 7.0). Retention times (min): tR 
of 1, 10.9; tR of 2, 6.8, A/B 20:80. 
 The concentration of N-benzyl-4-hydroxypyrrolidin-2-one 4 was analyzed by 
Shimadzu Prominence HPLC using a Hypersil BDS-C18 column (4 x 125 mm), UV 
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detection at 210 nm, flow rate of 1 mL/min; eluent A, acetonitrile, and eluent B, water. 
Retention times (min): tR of 1, 7.8; tR of 2, 2.8, A/B 20:80. 
 The ee of the 2 and 4 were analyzed by using the following conditions: Chiral 
column (250 m × 4.6 mm).  UV detection at 210 and 254 nm, flow rate at 1.0 mL/min 
(unless stated otherwise); eluent A, n-hexane; eluent B, isopropanol.  Retention times 
(min): tR of (R)-2, 26.1; tR of (S)-2, 43.5, column, chiralcel OB-H (Daicel), A/B 98/2; 
tR of (S)-4, 20.3; tR of (R)-4, 30.5, column, chiralpak AS, A/B 4/1. 
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Chapter 5 : Further Characterization of P450pyr and Related 
Mutants 
5.1 Introduction 
 Cytochrome P450 is a ubiquitous monooxygenase superfamily that can 
catalyze the insertion of an oxygen atom into C-H or C=C bonds. Its ability to 
catalyze regio- and stereoselective hydroxylation of non-activated carbon atoms plays 
a key role in biosynthetic pathways as well as in chemical synthesis of important 
intermediates for fine chemicals and pharmaceuticals. P450 enzymes also play a 
prominent role in the synthesis and metabolism of secondary metabolites such as 
prostaglandins,188 leucotrienes and thromboxanes,189 steroid hormones,190 insect and 
plant hormones,191 or colors and odors in plants.192 They are involved in the oxidative 
metabolism of pharmaceuticals and xenobiotic compounds in humans as well as bio-
degradation of environmental hazardous chemicals. In mammalian liver, P450 
monooxygenases function as a biological defense system.193 
 Bacterial P450s are more promising than those from plants and animals as 
they are mostly soluble, not membrane-associated, show higher reaction rates 
compared to P450s from other sources and exhibit a relatively high stability. To date, 
many of the bacteria P450s have been well characterized, such as P450BM-3 from 
Bacillus megaterium,194 CYP102A2 from Bacillus subtilis195 and CYP505 from 
Fusarium oxysporum,196 P450cam from Pseudomonas putida197 and P450nor from F. 
oxysporum198 among many others. Recently, P450cam, P450terp and P450BM-3 were 
shown to catalyze the oxidation of alternative substrates, such as the oxidation of 
substituted thioanisoles to sulfoxide and the epoxidation of substituted styrenes,199 
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with rather poor selectivity. The well-characterized camphor hydroxylase P450cam 
from Pseudomonas putida has been engineered to convert other substrates, including 
halogenated aromatic compounds such as alkylchlorobenzene.200,201 Another highly 
characterized and engineered P450 monooxygenase is P450BM-3 - a catalytically 
self-sufficient monooxygenase, which contains a heme domain and a flavin reductase 
domain on a single polypeptide chain.202,203 This self-sufficient system facilitates in 
vitro applications because the auxiliary electron transport protein partners are not 
required to be added separately for function. P450BM-3 has also been extensively 
evolved to a P450 propane monooxygenase (P450PMO) having 20 heme domain 
substitutions compared to WT P450BM-3.44  
 We are interested in the P450pyr from Sphingomonas sp. HXN-200 which 
belongs to a class I P450 monooxygenase and has been found to catalyze the 
hydroxylation of a broad range of substrates, such as n-alkanes, cyclic alkanes, N-
heterocycles, spiro-oxazolidines, and benzoxazole derivatives, with highly activity, 
high regioselectivity, and good to excellent enantioselectivity.10,126-130  In this chapter, 
we will focus on the partial characterization of cytochrome P450pyr and its 
enantioselective mutants that were previously engineered by stepwise site saturation 
mutagenesis. The WT P450pyr and its mutants 1AF4, 1AF4A and 11BB12 together 
with their auxiliary electron transport proteins, ferredoxin and ferredoxin reductase 
has also been successfully cloned and expressed in E. coli BL21(DE3). 
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5.2 Results 
5.2.1 Cloning, Expression, and Purification of WT P450pyr and Its Mutants 
 The WT P450pyr and ferredoxin (Fdx) gene from Sphingomonas sp. HXN200 
and the ferredoxin reductase (FdR) gene from Mycobacterium sp. HXN1500 were 
amplified from a plasmid pCom8-PA7F200R1500131. Meanwhile, the 1AF4, 1AF4A 
and 11BB12 mutants were amplified from the plasmid pRSFDuet containing the 
mutant P450s which were identified in the earlier rounds of directed evolution 
(Chapter 3). Next, each PCR-amplified gene was digested with its respective enzymes 
and cloned into the pET28a vector such that each gene would have an N-terminal 
His6-tag. Subsequently, the resulting plasmids were chemically transformed into 
chemical competent E. coli DH5α cells. Finally, the purified plasmids containing the 
correct gene was electroporated into electrocompetent E. coli BL21(DE3). 
 The constructed recombinant strains were each cultured separately in TB 
medium containing 50 µg/mL of kanamycin at 37 ºC. The gene expression was 
induced by adding 0.5 mM IPTG during the mid to late exponential phase, and the 
cells were continuously shaken at 250 rpm at 23 ºC for ~16-18 h. Standard enzyme 
purification protocol used has been described in the Materials and Methods section. 
SDS-PAGE analysis clearly revealed a thick band with the expected size of 
approximately 48 kDa for P450pyr, 47 kDa for FdR and 12 kDa for Fdx (Figure 5.1). 
The purified protein is estimated to have a purity of >90% based on the overloaded 
SDS-PAGE gel. The concentration of the purified protein was quantified using the 
Bradford protein assay. The CO difference spectrum was also used to quantify the 
active P450 concentration. 
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Figure 5.1. SDS-PAGE of purified proteins. P450pyr (lane 1), Fdx (lane 2) and FdR (lane 3). 
 
 
5.2.2 In vitro Kinetic Analysis 
 The steady state kinetic parameters for WT P450pyr, 1AF4, 1AF4A and 
11BB12 were determined from initial velocity measurements of the formation of 
product N-benzyl-3-hydroxypyrrolidines 2 from substrate N-benzyl pyrrolidine 1. The 
P450pyr and its mutants were reconstituted with the electron transport proteins Fdx 
and FdR. Initial activity assay indicated that increasing the Fdx concentration from 1 
to 10 µM while keeping the P450pyr and FdR concentration constant at 1 µM 
increases the specific activity of the P450pyr (Table 5.1). On the other hand, when the 
FdR concentration is increased from 1 to 10 µM, the specific activity of the P450 
decreases. When FdR is removed from the in vitro system, no activity was observed, 
confirming the fact that FdR is required for P450pyr activity. Further increase of the 
Fdx concentration beyond 10 µM showed no further increase in the P450 specific 
activity. Thus, we concluded that the optimum P450:Fdx:FdR is 1:10:1. 
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Table 5.1. Optimizing the ratio of P450:Fdx:FdR. Specific activity increases with increasing Fdx but 
decreases with increasing FdR. The reaction was conducted in the presence of the relevant enzymes in 
50 mM Tris HCl buffer, pH 7.5, containing 1 mM substrate 1 and 1 mM NADH. Total volume was 500 
µL. Product 2 formation was measured at 30 minutes. 
 Concentration / μM  
Sample P450pyr Fdx FdR Product 2 formation 
1 1 1 1 10.76 
2 1 5 1 44.20 
3 1 10 1 81.38 
4 1 20 1 81.09 
5 1 30 1 81.09 
6 1 40 1 62.33 
7 1 10 0 0 
8 1 5 1 47.04 
9 1 5 5 19.53 
10 1 5 10 8.27 
 
 Using this ratio, we proceeded to determine the saturating NADH 
concentration (P450 concentration is fixed at 0.5 µM) using different concentrations 
of NADH from 0.1 mM to 1 mM. The specific activity of the P450pyr reached its 
maximum at 0.2 mM NADH. Thus, we decided to use 1 mM NADH per 0.5 µM of 
P450, i.e. a five-fold oversaturation which should be more than sufficient. 
Table 5.2. Steady state kinetic parameters of WT P450pyr and its mutants 1AF4, 1AF4A and 11BB12. 
The values for kcat, KM and kcat/KM are based on the average of three separate kinetic assays. The 
kinetic assay for both 11BB12 and 1AF4 was based on an enzyme concentration of 0.5 µM whereas the 
1AF4A kinetic assay was based on 1 µM. 
Sample kcat (min-1) KM (mM) kcat/KM
WT P450 10.23 1.78 6.08 
11BB12 2.42 4.27 0.58 
1AF4 2.27 6.90 0.33 
1AF4A 1.11 9.11 0.13 
 
 Using the optimized conditions as determined previously, we ran the kinetic 
assays for WT P450, 1AF4, 1AF4A and 11BB12 (Table 5.2). When compared to the 
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WT P450pyr, the kcat of the mutants was reduced by more than four-fold whereas the 
KM was increased by more than two-fold. Among the mutants, 11BB12 has the 
highest kcat of 2.42 min-1 and the lowest KM value of 4.27 (based on 0.5 µM of 
enzyme). 1AF4 shared a similar kcat value to 11BB12 although the KM value is 1.6 
fold higher at 6.9 mM. 1AF4A also demonstrated the lowest kcat of only 1.11 min-1 
and a high KM of 9.11 (based on 1 µM of enzyme). 
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Figure 5.2. Michaelis-Menten plot for WT P450pyr. 
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Figure 5.3. Michaelis-Menten plot for 11BB12. The maximum substrate concentration used was 
capped at 10 mM as the solubility of the substrate in aqueous solution is noticeably reduced beyond 15 
mM. 
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Figure 5.4. Michaelis-Menten plot for 1AF4. The maximum substrate concentration used was capped 
at 10 mM as the solubility of the substrate in aqueous solution is noticeably reduced beyond 15 mM.  
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Figure 5.5. Michaelis-Menten plot for 1AF4A. The maximum substrate concentration used was capped 
at 10 mM as the solubility of the substrate is noticeably reduced beyond 15 mM.  
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5.2.3 Biohydroxylation of Mutant P450s with Different Substrates 
 WT P450pyr has previously been shown to have a wide substrate range, 
including piperidines, pyrrolidinones and piperidinones.127-130 Hence, we are 
interested in investigating the changes in product ee when 1AF4 and 1AF4A mutants 
are used to catalyze the hydroxylations of a range of different substrates using whole-
cell assays. In this experiment, we have biohydroxylated following substrates to their 
corresponding alcohols: N-benzyl pyrrolidine 1 (our original substrate), N-
benzyloxycarbonyl-pyrrolidine 3, N-Boc-pyrrolidine 5, N-benzyl pyrrolidinone 7, N-
Boc- pyrrolidinone 9, N-benzyl piperidinone 11, and N-Boc-piperidinone 13 (Figure 
5.6). 
 
Figure 5.6. Hydroxylation scheme of various substrates to their respective products. 
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Table 5.3. Product ee of various substrates. 
Substrates WT ee (%) 1AF4 ee (%) 1AF4A ee (%) 
1 43 (S) 42 (R) 83 (R) 
3 75 (R) 78 (R) Formation of a side product 
which overlaps with the 
enantiomeric peaks 
5 4 (R) 8 (R) 21 (R) 
7 > 99.9 (S) 99 (S) 99 (S) 
9 90-92 (S) 90 (S) 90 (S) 
11 55 (S) 60 (S) 44 (R) 
13 28 (R) 9 (R) 73 (S) 
 
 From a previous directed evolution work, we found that both 1AF4 and 
1AF4A can invert the WT P450 enantioselectivity towards substrate 1. Here, we 
found that both 1AF4 and 1AF4A can also change the enantioselectivity towards 
substrate 11 and 13 (Table 5.3). In fact, 1AF4A could invert the ee of substrate 11 and 
13 (Figure 5.7 and 5.8). There was hardly a change in enantioselectivity for substrates 
3, 7 and 9. Although the enantioselectivity was slightly improved towards substrate 5, 
it is still poor. 
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Figure 5.7. Chiral HPLC spectra for the biohydroxylation with substrate 11. 
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Figure 5.8. Chiral HPLC spectra for the biohydroxylation with substrate 13. 
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5.3 Discussion 
 Six enzymes i.e. WT P450pyr, its mutants 11BB12, 1AF4 and 1AF4A, and its 
redox partners Fdx and FdR were successfully cloned into pET28a to introduce an N-
terminal His6-tag upstream of the enzyme. The enzymes were expressed in E. coli 
BL21(DE3) and purified using Ni-NTA gravity flow column. For the first time, the 
P450pyr and its mutants were reconstituted successfully together with their electron 
transport proteins, Fdx and FdR, and the steady state kinetic parameters were 
determined. Although the mutants 11BB12, 1AF4 and 1AF4A have higher 
enantioselectivities, the mutation(s) in the active site region have lowered the 
enzyme’s specific activity and increased its KM. This is not totally unexpected, and 
this problem can perhaps be resolved easily with another round of directed evolution 
(e.g. error-prone PCR) focusing on other areas other than the active pocket to evolve 
an enzyme which has a higher activity and stability. 
 When 1AF4 and 1AF4A were used to biohydroxylate different substrates, we 
found that there was hardly any change in enantioselectivity for substrates 3, 7 and 9 
and only a slight change for substrate 5. The biohydroxylation of substrate 11 and 13 
by 1AF4A showed an inversion of the enantioselectivity. The resistance to changes in 
enantioselectivity asserts that the enantioselectivity of each substrate is governed by 
different residues in the active pocket of the P450pyr. Since our P450pyr was 
engineered using substrate 1, the selected mutants would result in a significant change 
of enantioselectivity in substrate 1 but not necessarily other substrates. Different 
substrates would interact differently with each residue within the active site due to the 
changes in substrate size as well as the hydrophobic and hydrophilic effect of 
different directing groups in incoming substrates. 
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5.4 Conclusion and Outlook 
 We have successfully reconstituted the P450pyr and its mutants with its 
electron transport proteins Fdx and FdR in vitro. The P450pyr mutants showed poor 
kcat and KM which also corresponds to its low activity in whole-cell assays reported in 
chapter 3.  Also, biohydroxylation of the P450pyr mutants with different substrates 
revealed interesting results, especially for substrates 11 and 13 which showed a 
reversal in enantioselectivity when biohydroxylated with 1AF4A. 
 In order to elucidate the relationship and interaction between residues in the 
P450pyr active pocket and different substrates, it would necessary to crystallize the 
P450pyr together with its bound substrate. The crystal structure of P450pyr would 
give fascinating new insights into how the residues within the active pocket could 
affect the biohydroxylation enantioselectivity of the P450pyr.  Future work will focus 
on performing more detailed characterizations of the P450pyr and its mutants and 
investigating methods to help increase the activity and enantioselectivity of the 
P450pyr. 
 
5.5 Materials and Methods 
Materials 
 Escherichia coli BL21(DE3) and the expression plasmids were purchased 
from Novagen (Madison, WI). PCR grade dNTPs were obtained from Roche Applied 
Sciences (Indianapolis, IN). Restriction enzymes, Phusion High-Fidelity DNA 
polymerase, T4 DNA ligase and their corresponding buffers were purchased from 
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New England Biolabs (NEB) (Beverly, MA). D-glucose was purchased from 
ThermoFisher (Pittsburgh, PA). Ampicillin, kanamycin, isopropyl β-D-
thiogalactopyranoside (IPTG), nitro blue tetrazolium (NBT), phenazine methosulfate 
(PMS), NAD+, and NADP+ were purchased from Sigma (St. Louis, MO). The Ni-
NTA agarose, QIAprep spin plasmid mini-prep kit, QIAEX II gel purification kit, and 
QIAquick PCR purification kit were purchased from Qiagen (Valencia, CA). Various 
oligonucleotide primers were obtained from Integrated DNA Technologies (Coralville, 
IA). SDS-PAGE gels, buffers and protein size markers were purchased from Bio-Rad 
(Hercules, CA). All other required chemical reagents and solvents were purchased 
from Acros Organics (Morris Plains, NJ) and Sigma-Aldrich (St. Louis, MO). N-
benzyloxycarbonyl-pyrrolidine 3 was synthesized according to known procedures.204 
Cloning of WT P450pyr, 11BB12, 1AF4, 1AF4A, Fdx and FdR 
 Each gene (WT P450pyr, 11BB12, 1AF4, 1AF4A, Fdx and FdR) was 
individually amplified using the template and primers listed in Table 5.4. PCRs were 
carried out in an MJ Research PTC-200 thermal cycler using the following program: 
PCR program: 
1 = 98 °C for 0:30 
2 = 98 °C for 0:10 
3 = 55-65 °C for 0:45 
4 = 72 °C for 1:00 
5 = Goto 2, 24 times 
6 = 72 °C for 10:00 
7 = 4 °C for ever 
8 = End 
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 The PCR products were digested with NdeI and XhoI or HindIII and cloned 
into their respective sites in pET28a vector in order to express proteins as His6-tag 
fusions.  The resulting plasmids were transformed E. coli DH5α, checked with 
restriction digestion, sequenced and transformed into E. coli BL21(DE3). 
Table 5.4. Primers and templates used to amplify 7 different genes 
Gene to be amplified Primers (Restriction sites 
underlined) 
Template 
WT P450pyr P450 NdeI Fwd: TTA ACT 
ACT CAT ATG GAA C AT 
ACA GGA CAA AGC GCG 
N-P450 XhoI Rev: TTA ACT 
CTC GAG CTA CGC GTG 
GAC GCG AAC 
 
Primers used in overlap 
extension PCR: 
P450 982 fwd: CGCTT GCT 
CAC ATG CGC CGCA      
P450 982 rev: TGCG GCG 
CAT GTG AGC AAGCG 
 
pCom8-PA7F200R1500131 
Note: The NdeI site (CAT ATG) 
in the P450pyr gene was replaced 
with CAC ATG by site directed 
mutagenesis using overlap 
extension PCR. 
11BB12 P450 NdeI Fwd: TTA ACT 
ACT CAT ATG GAA C AT 
ACA GGA CAA AGC GCG 
N-P450 XhoI Rev: TTA ACT 
CTC GAG CTA CGC GTG 
GAC GCG AAC 
pRSFDuet 11BB12 (from 
directed evolution step) 
1AF4 P450 NdeI Fwd: TTA ACT 
ACT CAT ATG GAA C AT 
ACA GGA CAA AGC GCG 
 
N-P450 XhoI Rev: TTA ACT 
CTC GAG CTA CGC GTG 
GAC GCG AAC 
 
pRSFDuet 1AF4 (from directed 
evolution step) 
1AF4A P450 NdeI Fwd: TTA ACT 
ACT CAT ATG GAA C AT 
ACA GGA CAA AGC GCG 
 
N-P450 XhoI Rev: TTA ACT 
CTC GAG CTA CGC GTG 
GAC GCG AAC 
 
pRSFDuet 1AF4A (from directed 
evolution step) 
Fdx Fdx NdeI Fwd: TTA ACT ACT 
CAT ATG CCA ACA GTG 
ACC TAT GTT GAA ATA 
AAT GG 
 
Fdx XhoI Rev: TTA ACT ACT 
pCom8-PA7F200R1500 
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CTC GAG TCA ATG CTG 
CGC GAG AGG AAG 
 
FdR Red NdeI Fwd: TTA ACT ACT 
CAT ATG ATC CAC ACC 
GGC GTG AC 
 
Red HindIII Rev: TTA ACT 
ACT AAG CTT TTA GAG 
GGA GGT TGG GGA CG 
pCom8-PA7F200R1500 
 
Overexpression, and the Purification of WT P450pyr, 11BB12, 1AF4, 1AF4A, 
Fdx and FdR 
 E. coli BL21(DE3) cells overexpressing the gene of interest were grown in TB 
medium supplemented with kanamycin (50 µg mL-1).  Cells were grown at 37 °C to 
OD600 of ~0.6 and then induced at 25 °C by the addition of IPTG to a final 
concentration of 0.25 mM.  An additional 0.5 mM of δ-aminolevulinic acid was added 
to the culture that was expressing P450pyr or its mutants. The culture was incubated 
at 25 °C for an additional 16 to 18 hours, after which the cells were harvested by 
centrifugation (10 minutes at 6,000 rpm) and resuspended in cold 10 mM imidazole 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). Lysozyme (1 
mg/mL) was added to the resuspended cells and the sample was freeze-thawed. The 
cells were further lysed by two passes through the French press. The cell debris was 
removed by centrifugation (20 minutes at 19,000 rpm, 4 ºC) and the supernatant 
containing the soluble protein was syringe filtered (Millipore Millex-GP Filter, 0.2 
µM). 
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 The N-His6-tagged-proteins were purified using gravity flow columns 
containing 3 mL of Qiagen Ni-NTA agarose. The resin was equilibrated with 10 mM 
imidazole buffer according to the manufacturer’s instructions. The clarified 
supernatant was loaded onto the resin and contaminating E. coli proteins were washed 
with 60 mL of 10 mM imidazole buffer, 60 mL of 20 mM imidazole buffer, 30 mL of 
30 mM imidazole buffer and 3 mL of 50 mM imidazole buffer. The targeted proteins 
were eluted with 200 mM imidazole buffer and the protein fractions were analyzed 
using the Bradford reagent (Bio-Rad).  Fractions containing the protein were pooled 
together and concentrated a using Millipore Amicon Ultra-4 centrifugal filter device 
(MWCD 10 kDa) at 4,000 rpm at 4 °C, washed three times with 50 mM potassium 
phosphate buffer (pH 7.5), and concentrated again. Concentrated protein was stored at 
-80 °C in 15% glycerol. Protein concentration was determined using the calculated 
molar extinction coefficient at 280 nm (SDSC Biology Workbench - 
http://workbench.sdsc.edu/) or by using Bradford protein assay. 
 
CO Difference Spectrum of P450pyr 
 10 µL of purified P450pyr was diluted 80 fold to a total volume of 800 µL by 
adding 10 mM potassium phosphate buffer (pH 7.5) in a quartz cuvette. The protein 
was first reduced by adding 15 mg of sodium hydrosulfite (Sigma-Aldrich) and 
saturated with CO by bubbling the gas for about 20 sec. The UV absorbance at 450 
nm of the protein was measured before and after the CO bubbling. A molar extinction 
coefficient for P450 of 90 cm-1 was used to calculate the P450pyr concentration. 
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Enzyme Kinetics (In vitro Assay) 
 The enzyme activities of P450pyr, 11BB12, 1AF4 and 1AF4A were routinely 
assayed by HPLC.  The assay mixture (0.5 mL final volume) contained 0.5 µM P450, 
5 µM Fdx, 10 µM FdR, substrate 1, and 1 mM NADH in 50 mM Tris HCl buffer at 
pH 7.5.  Reactions were initiated by the addition of different amounts of substrate 1 to 
the reaction mixture and incubated at 30 °C. Samples (100 µL) were taken at 10 sec, 1 
min, 5 min, and 9 min and were quenched by adding 20 µL of 4 % (v/v) 
trifluoroacetic acid (TFA).  The samples were then analyzed by reverse phase HPLC.  
The Michaelis-Menten equation was fitted to the data using non-linear least squares 
regression analysis in Microcal Origin 5.0 (OriginLab Corporation, Northampton, MA) 
to determine kcat and KM values. 
Reverse Phase HPLC Analysis for N-Benzyl pyrrolidine 1 and N-Benzyl-3-
hydroxypyrrolidines 2 
 The following conditions were used to analyze samples: Agilent Eclipse Plus 
C18 (3.5 µm) column (4.6 x 150 mm), UV detection at 210 nm, flow rate of 0.9 
mL/min; eluent A, acetonitrile, and eluent B, 10 mM potassium phosphate buffer (pH 
7.0). Retention times (min): tR of 1, 6.8; tR of 2, 10.9, A/B 20:80. 
General Procedure for the Biohydroxylation of Different Substrates with Whole-
Cells  
 E. coli cells (BL21(DE3) pRSFDuet P450 pETDuet FR) overexpressing the 
WT P450 or its mutants (1AF4 and 1AF4A), as well as the Fdx and FdR were grown 
in 35 mL TB medium supplemented with 50 µg/mL kanamycin and 100 µg/mL 
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ampicillin.  Cells were grown at 37 °C to OD600 of ~0.6 and then induced at 30 °C by 
the addition of IPTG and δ-ALA to a final concentration of 0.5 mM.  The culture was 
incubated at 30 °C for an additional 4 hours, after which the cells were harvested by 
centrifugation (10 minutes at 4,000 rpm) and resuspended in potassium phosphate 
buffer (50 mM, pH 7.5) containing 2 % (w/v) glucose to obtain a cell density of 8 g 
cell dry weight (cdw)/L. 1 mL of cells suspension was aliquoted into different 2 mL 
microcentrifuge tubes and  4 µL of each substrate (stock solution of 0.5 M) was added 
into each tube separately. The tubes were shaken at 30 ºC and 1200 rpm for 4 h with a 
BIOER (Hangzhou, China) mixing block MB-102. The tubes were then centrifuged 
and the supernatant was extracted for further work-up. 
Work-up Procedure for Biohydroxylation of Substrates 1, 3, 5, 7, 9, 11 and 13 
 A quick and simple work-up procedure was used in this work. The cells were 
removed from the bioconversion mixture by centrifugation, and the supernatant was 
adjusted to pH 11-12 by addition of 20 µL of 5 N KOH, followed by extraction with 
ethyl acetate. The organic phase was separated and the solvent was removed by quick 
evaporation using a Thermo Scientific SpeedVac concentrator. The product was then 
resuspended in 100 µL of isopropanol and analyzed with chiral HPLC. 
Determination of ee of Bioproducts 2, 4, 6, 8, 10, 12 and 14 
 The following conditions were used to analyze samples: Chiral column (250 m 
× 4.6 mm).  UV detection at 210 and 254 nm, flow rate at 1.0 mL/min (unless stated 
otherwise); eluent A, n-hexane; eluent B, isopropanol.  Retention times (min): tR of 
(R)-2, 26.1; tR of (S)-2, 43.5, column, chiralcel OB-H (Daicel), A/B 98/2; tR of (S)-4, 
13.5; tR of (R)-4, 15.4, column, chiralpak AS, A/B 9/1; tR of (S)-6, 34.8; tR of (R)-6, 
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39, column, chiralpak AS, A/B 99/1; tR of (S)-8, 20.3; tR of (R)-8, 30.5, column, 
chiralpak AS, A/B 4/1; tR of (R)-10, 17.9; tR of (S)-10, 22.6, column, chiralcel OB-H, 
A/B 7/1, flow 0.5 mL/min; tR of (S)-12, 8.7; tR of (R)-12, 10.4, column, chiralpak AS, 
A/B 75/25; tR of (S)-14, 28.3; tR of (R)-14, 30.8, column, chiralcel OB-H, A/B 95/5, 
flow 0.5 mL/min. 
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Chapter 6 :  Conclusion and Recommendations 
6.1 Conclusion 
 The recent discovery of a novel P450pyr enzyme from Sphingomonas sp. 
HXN-200, a class I P450 monooxygenase, has led to the discovery of new synthetic 
applications of biocatalytic hydroxylations of non-activated carbon atoms, as this 
enzyme is able to catalyze the hydroxylation of a broad range of substrates, such as n-
alkanes, cyclic alkanes, N-heterocycles, spiro-oxazolidines, and benzoxazole 
derivatives, with reasonably high activity, regioselectivity and enantioselectivity.127-
129 In this thesis, we seek to investigate and engineer this novel P450pyr at a 
molecular level in order to further develop our understanding of its biological 
functions and its potential as an environmental friendly biocatalyst in the chemist’s 
tool box. 
 There has been many ‘firsts’ in this thesis. For the first time, a highly active 
Escherichia coli recombinant expressing the P450pyr and its electron transport 
proteins ferredoxin (Fdx) from Sphingomonas sp. HXN200 and the ferredoxin 
reductase (FdR) from Mycobacterium sp. HXN1500 was constructed. We have also 
developed the first high-throughput colorimetric ee assay that was used in the directed 
evolution of a P450 for asymmetric biohydroxylations. This method was found to be 
very sensitive, independent of concentration, and takes only a few seconds to measure 
each 96-well microtiter plate. In addition, we have developed a high-throughput mass 
spectrometry (MS)-based screening method which has high accuracy in ee 
determination and can be used for different hydroxylation reactions, independent of 
the biocatalyst. Other advantages of this MS-based method are its high sensitivity, 
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speed, and simplicity as it allows the direct analysis of samples taken from the 
supernatant of biohydroxylation reactions. 
 We have also reported the first example where directed evolution, coupled 
with a high-throughput enantioselectivity screening system, has been applied to 
improve the biohydroxylation enantioselectivity of a class I P450 monooxygenase 
using a prochiral substrate. We have succeeded in inverting the enantioselectivity of 
the P450pyr towards the biohydroxylation of prochiral substrate N-benzyl-3-
hydroxypyrrolidine by iterative targeted site-saturation mutagenesis coupled with a 
high-throughput two-enzyme-based colorimetric assay. An interesting observation to 
note was that one mutation at position 100 was all it took to completely invert the 
enantioselectivity of the P450pyr. The best mutant 1AF4A has an ee of 83% (R) 
compared to the wild type’s ee of 43% (S).  
 In order to increase the efficiency and productivity of the P450pyr-catalyzed 
hydroxylation reaction, two cofactor regeneration systems utilizing either the glucose 
dehydrogenase118 (GDH) from Bacillus substilis BGSC 1A1 or the engineered 
phosphite dehydrogenase 12x33,123 (PTDH 12x) from Pseudomonas stutzeri were 
incorporated together with the P450pyr system in vivo. As a result, we have 
developed several strains of E. coli which have shown up to 2.5x improvement in 
specific activity compared to the parent strain which did not have the cofactor-
regeneration system. The phosphite dehydrogenase-based cofactor regeneration 
system was also found to have better pH-buffering since the side product of the 
phosphite dehydrogenase system is phosphate which can act as a buffer while the 
glucose dehydrogenase produces an acidic gluconolactone. 
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6.2 Recommendations/ Future Work 
 Although we have succeeded in improving the enantioselectivity of the 
P450pyr, the activity of the enzyme was negatively affected. This is not totally 
unexpected as the introduction of mutations to its heme active site by iterative 
targeted site-saturation mutagenesis has probably introduced a destabilizing effect in 
the protein. Hence, it would be necessary to take a step back to increase the P450pyr 
stability and activity by random mutagenesis before attempting to proceed with 
further rounds of mutagenesis to improve the enzyme’s enantioselectivity. With 
increased stability, the enzyme would have more room to evolve as it can tolerate 
highly destabilizing mutations.174.  
 Using our directed evolution approach, we have also discovered the (S)-
enantioselective mutant 11BB12 that has an ee of 65% (S). It would be interesting if 
we could utilize a different directed evolution approach, e.g. CASTing205 or gene 
shuffling, coupled with the high-throughput mass spectrometry-based screening 
method to evolve an (S)-enantioselective mutant with a much higher 
enantioselectivity (i.e. >90%) 
 In order to further characterize our P450pyr mutants, it would be necessary to 
crystallize the P450pyr mutants together with their bound substrate. The crystal 
structure of wild type P450pyr and its mutants would give us a deeper understanding 
of the structure-function relationship of the residues in the P450pyr active pocket and 
enable us to predict how certain residues within the active pocket could affect the 
biohydroxylation enantioselectivity of the P450pyr.  
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 The in vivo cofactor regeneration system which we have developed can also be 
applied to the production of different substrates or used in other microbial 
biohydroxylation reactions. We could also explore different promoters, plasmid and 
gene combinations, as well as different reaction conditions to further improve the 
productivity of the biohydroxylation system. In a different approach, we could utilize 
the enzymes co-immobilization on nanoparticles method206 to further improve the 
productivity of the P450pyr system. The advantages of this nanoparticle 
immobilization system include recyclability of nanoparticles, high dispersity, larger 
enzyme loading amounts and lower mass transfer resistance, thus leading to higher 
turnover rates. 
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